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Abstract
The Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to deliver a
scientiﬁc opinion on the safety of monacolins in red yeast rice (RYR) and to provide advice on a
dietary intake of monacolins that does not give rise to concerns about harmful effects to health. The
Panel reviewed the scientiﬁc evidences available as well as the information provided by interested
parties in response of a public ‘Call for data’ launched by EFSA. The Panel considered that monacolin
K in lactone form is identical to lovastatin, the active ingredient of several medicinal products
authorised for the treatment of hypercholesterolaemia in the EU. On the basis of the information
available, the Panel concluded that intake of monacolins from RYR via food supplements, could lead to
estimated exposure to monacolin K within the range of the therapeutic doses of lovastatin. The
Panel considered that the available information on the adverse effects reported in humans were
judged to be sufﬁcient to conclude that monacolins from RYR when used as food supplements were
of signiﬁcant safety concern at the use level of 10 mg/day. The Panel further considered that
individual cases of severe adverse reactions have been reported for monacolins from RYR at intake
levels as low as 3 mg/day. The Panel concluded that exposure to monacolin K from RYR could lead to
severe adverse effects on musculoskeletal system, including rhabdomyolysis, and on the liver. In the
reported cases, the product contained other ingredients in addition to RYR. However, these reported
effects in particular musculoskeletal effects, have both occurred after ingestion of monacolin K and
lovastatin independently. On the basis of the information available and several uncertainties
highlighted in this opinion, the Panel was unable to identify a dietary intake of monacolins from RYR
that does not give rise to concerns about harmful effects to health, for the general population, and as
appropriate, for vulnerable subgroups of the population.
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Summary
Following a request from the European Commission, the EFSA Panel on Food Additives and Nutrient
Sourced Added to Food (ANS) was asked to deliver a scientiﬁc opinion on the evaluation of monacolins
in red yeast rice (RYR) in accordance with Article 8 (2) of Regulation (EC) No 1925/2006 on the
addition of vitamins and minerals and of certain other substances to foods.
In respect to the approach to be followed for the assessment of monacolins, the ANS Panel was of
the view that previous assessments, when relevant to the safety issues that triggered the Article 8
procedures, should be used as starting points for this scientiﬁc opinion. The effect of other possible
ingredients of food supplements on monacolins bioactivity is not considered in this opinion.
The current evaluation is based on the published scientiﬁc literature available up to May 2018,
monographs and risk assessment reports by national and international authorities and the data
available following the launch of a public ‘Call for data’.
RYR is made by fermentation of rice with yeasts, mainly Monascus purpureus. RYR is traditionally
used in China for culinary purposes as a food colouring or as a traditional remedy to promote digestion
and blood circulation.
In 2013, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) issued a scientiﬁc
opinion on the substantiation of a health claim related to monacolin K from RYR and maintenance of
normal blood LDL-cholesterol concentration. The NDA Panel concluded that a cause and effect
relationship had been established between the consumption of 10 mg/day of monacolin K from RYR
and the claimed effect.
The ANS Panel considered that monacolin K in lactone form is identical to lovastatin, the active
ingredient of several medicinal products authorised for the treatment of hypercholesterolaemia in the
European Union (EU).
On the basis of the data received from interested parties in response of a public ‘Call for data’
launched by EFSA, the Panel noted that the recommended daily intake of monacolin K from RYR ranges
from 9 to 20 mg. The Panel further noted that the recommended daily intake of 20 mg of monacolin K
is reported for one product only that according to the interested party is planned to be delisted.
For the purpose of this scientiﬁc opinion, the Mintel Global New Products Database (Mintel
GNPD) was used for checking the labelling of products containing monacolin K from RYR within the EU
countries’ food products as the Mintel GNPD shows the compulsory ingredient information presented in
the labelling of products. According to the Mintel GNPD, monacolin K was labelled on 40 products
between January 2012 and February 2018. The food category considered was: ‘Vitamins & Dietary
Supplements’. The concentrations of monacolin K were also retrieved from this database, when
available. In all these products, the content of monacolin K was clearly stated. The daily consumption
in terms of monacolin k for each product was calculated by multiplying the intake unit of monacolin
K by the daily number of recommended intakes of the product.
The recommended daily intakes range between 2 and 48 mg of monacolin K, but the majority of
food supplements (around 25%) supplies a recommended a daily intake of 10 mg according to the level
established by the European Food Safety Authority (EFSA) for supporting the health claim (EFSA NDA
Panel, 2013). The Panel noted that only 8 out of 40 products were mono-ingredient, containing only RYR
preparation; in the remaining 32 products, the most frequently associated ingredients were artichoke
extract, berberine (Berberis aristata), coenzyme Q10, chromium, policosanol, resveratrol and vitamins.
On the basis of the information retrieved from the Mintel GNPD, the Panel noted that two products
reported recommended daily intake of 20 or 48 mg of monacolin K.
Monacolin K and lovastatin are rapidly converted from their lactone to an identical hydroxy acid (HA)
form, the latter being responsible for the inhibition of the 3-hydroxy-3 methylglutaryl-coenzyme A
(HMG-CoA) reductase enzyme involved in the biosynthesis of cholesterol. While the acidic form is naturally
occurring in RYR, in the case of lovastatin its generation requires conversion from the lactone form.
The bioavailability of lovastatin increases by 30–50% when taken with a standard meal. Due to the
involvement of the CYP3A4 isoform in its metabolism, interactions with drugs or food ingredients which
are inhibitors of this enzyme have been described, leading to increased plasma levels of statins and
possible increased risk of toxic effects. There are indications to support the fact that the monacolin K
in RYR may have a different concentration–time proﬁle compared to the corresponding lovastatin. Two
studies present conﬂicting results. In the ﬁrst one, the serum concentration of monacolin K (in the two
forms of lactone and HA) was signiﬁcantly higher (approximately 4 times) when the subjects were
orally administrated with an equivalent intake of monacolin K from RYR or lovastatin (Chen et al.,
2013). In this study, an intake of 5–6 mg of monacolin K was considered by the authors bioequivalent
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to 20–40 mg of lovastatin. The study by Li et al. (2005) indicates instead an opposite result, which
could have been inﬂuenced by the pretreatment and simultaneous administration of grapefruit juice, a
known CYP3A4 inhibitor.
The Panel noted that in some cases, the intake of RYR was associated with other botanicals (either
in multi-ingredient preparations or concomitantly) or other medicinal products, which could be
responsible for any side effect(s). However, the reported side effects, in particular musculoskeletal side
effects with elevated creatine phosphokinase (CPK) up to several thousand units have occurred after
ingestion of monacolin K and lovastatin but not after ingestion of other botanical ingredients.
The therapeutic dose of lovastatin ranges between 10 and 80 mg/day. Considering six clinical trials,
where RYR was the only treatment used to reduce hypercholesterolaemia, it was shown that changes
in total cholesterolaemia and LDL-cholesterolaemia were dose-dependent. The lowest intake of
monacolin K, which was effective in reducing total cholesterolaemia (11.2%) and LDL-
cholesterolaemia (14.8%) was 3 mg/day.
According to four clinical studies (Dujovne et al., 1991; Furberg et al., 1994; Weintraub et al.,
1994; Downs et al., 2001), the published case reports, and EMA Pharmacovigilance, the most frequent
adverse effects to lovastatin have as a target the following organs/systems, in decreasing order of
frequency: musculoskeletal and connective tissue, including rhabdomyolysis (53.4% of EMA reports),
nervous system (20.3%), gastrointestinal tract (14.9%), kidney (11.3%), liver (10%), skin and
subcutaneous tissue (8.9%), and other minor targets.
The Panel noted that the proﬁle of adverse effects to RYR is similar to that of lovastatin; through
consultation of four sources of case reports (WHO, ANSES, Italian Surveillance system, FDA), the most
important targets for adverse events are: (1) musculoskeletal and connective tissue (29.9–37.2% of
cases, including 1–5% of rhabdomyolysis); liver (9–32%); nervous system (when reported, 12.8–
26.9%); gastrointestinal tract (12–23.1%); skin and subcutaneous tissue (8–17.3%).
The Panel noted that in some cases, the intake of RYR was associated with other botanicals (either
in multi-ingredient preparations or concomitantly) or other medicinal products, which could be
responsible for any side effect(s). However, the reported side effects, in particular musculoskeletal side
effects with elevated CPK up to several thousand units have occurred after ingestion of monacolin K
and lovastatin but not after ingestion of other botanical ingredients.
Case reports specifying the daily intake of monacolin K showed that adverse effects appeared also
with the intake of 3 mg/day for period ranging between 2 weeks and 1 year. Cases of rhabdomyolysis,
hepatitis and skin disorders occurred and required hospitalisation (Mazzanti et al., 2017).
With respect to the data collected on the safety of use of RYR (and in particular of monacolins), the
Panel identiﬁed the following uncertainties:
• the composition and content of monacolins (and their relative abundance) in food supplements
containing RYR;
• monacolins in RYR are used in multi-ingredients botanical preparations, the components of
which have not been fully evaluated individually or in combination;
• the ratio between monacolin K lactone and monacolin K HA is variable in food supplements
containing RYR;
• lack of data on the bioactivity of components in RYR other than monacolin K;
• due to the lack of data, the safe use of monacolins in certain groups of consumers cannot be
evaluated (pregnant women, nursing women, breastfed infants);
• the effects of concomitant consumption of RYR-based food supplements with foods or drugs
inhibiting CYP3A4;
• in the majority of cases, RYR-based food supplements are multi-ingredients products.
Interactions with other ingredients on the safety of monacolins are unknown.
The Panel concluded that monacolin K in lactone form is identical to lovastatin, an active ingredient
of several medicinal products.
The Panel further concluded that intake of monacolins from RYR via food supplements, could lead
to estimated exposure to monacolin K within the range of the therapeutic doses of lovastatin.
The Panel considered that the available information on the adverse effects reported in humans
were judged to be sufﬁcient to conclude that monacolins from RYR when used as food supplements
were of signiﬁcant safety concern at the use level of 10 mg/day. The Panel further considered that
individual cases of severe adverse reactions have been reported for monacolins from RYR at intake
levels as low as 3 mg/day.
Safety assessment of monacolins
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The Panel concluded that exposure to monacolin K from RYR could lead to severe adverse effects on
musculoskeletal system, including rhabdomyolysis, and on the liver. In the reported cases, the product
contained other ingredients in addition to RYR. However, these reported effects, in particular
musculoskeletal effects, have both occurred after ingestion of monacolin K and lovastatin independently.
On the basis of the information available and several uncertainties highlighted in this opinion, the
Panel was unable to identify a dietary intake of monacolins from RYR that does not give rise to
concerns about harmful effects to health, for the general population, and as appropriate, for
vulnerable subgroups of the population.
Safety assessment of monacolins
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1. Introduction
Following a request from the European Commission to the European Food Safety Authority (EFSA),
the Scientiﬁc Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to provide
a scientiﬁc opinion on the safety of monacolins from red yeast rice (RYR).
This risk assessment was carried out in the framework of the procedure under Article 8(2) of
Regulation (EC) No 1925/2006 on the addition of vitamins and minerals and of certain other
substances to foods, for monacolins from RYR, initiated by the European Commission. Article 8(2) of
Regulation (EC) No 1925/2006 is referring to a possible prohibition, restriction or Community scrutiny
of a substance or ingredient by placement in Annex III, Part A, B or C of this Regulation.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
In 2011 and 2013, the European Food Safety Authority (EFSA) issued opinions on the scientiﬁc
substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal
blood LDL-cholesterol concentrations.1 In these opinions, the EFSA Panel concluded that a cause and
effect relationship has been established between the consumption of monacolin K from red yeast rice and
maintenance of normal blood LDL-cholesterol concentrations. In relation to restrictions of use, the EFSA
Panel referred to the Summary of Product Characteristics (SmPC) of lovastatin-containing medicinal
products available on the EU Market. In the SmPC for such products, special warnings and precautions for
use refer to the risk of myopathy/rhabdomyolysis, which is increased by concomitant use of lovastatin with
certain other medicinal products, and discouraged use of lovastatin by pregnant and lactating women.
EFSA and its opinions also made reference to the EFSA CONTAM Panel’s opinion on citrinin (a
nephrotoxic mycotoxin),2 which can be produced by some strains of Monascus purpureus.
The presence of citrinin in red yeast rice preparations has not been an issue of concern, since the
adoption of Commission Regulation (EU) No 212/2014 of 6 March 2014 amending Regulation (EC) No
1881/2006 as regards maximum levels of the contaminant citrinin in food supplements based on rice
fermented with red yeast Monascus purpureus.3
Furthermore, the French Agency for Food, Environmental and Occupational Health & Safety
(ANSES) in its opinion4 on the risk associated with the presence of “red yeast rice” in food
supplements concluded that “due to the composition of red yeast rice and in particular: the presence
of monacolin K (also called lovastatin when marketed as a drug) that shares the adverse effects of
statins; the presence at varying levels of the other monacolins, compounds whose safety has not been
established, consumption of “red yeast rice” exposes some consumers to a health risk”.
On 13 February 2016, the Belgian Superior Health Council adopted a scientiﬁc advisory report5 that
“provides an evaluation of the supposed beneﬁcial effects and possible toxicity of dietary supplements
based on red yeast rice for the Belgian population”, and the report “also provides speciﬁc
recommendations to the authorities in charge of public health and nutrition policies, healthcare
professionals and the general population”. This report refers to the risk associated with the presence of
monacolins, in particular monacolin K, in red yeast rice that include adverse effects identical to those
observed in patients taking statin drugs. The report concludes that the main toxic effect is muscular
with a risk of renal failure in the case of rhabdomyolysis, and that functional digestive disorders are
common, however hepatotoxicity is relatively rare.
The report further concludes that certain vulnerable group are at a higher risk of developing toxic
effects, including pregnant women, people suffering from liver, kidney and muscle disorders, persons
aged over 70 years and children and adolescents.
Other relevant scientiﬁc assessments include a “toxicological evaluation of red mould rice” carried
out in 2013 by the German research funding organisation DFG.6 This assessment concludes that “red
mould rice is not a safe food/food supplement”.
1 EFSA Journal 2011;9(7):2304; EFSA Journal 2013;11(7):3327; EFSA Journal 2013;11(2):3084.
2 EFSA Journal 2012; 10(3):2605.
3 OJ l 67, 7.3.2014, p. 3.
4 https://www.anses.fr/en/system/ﬁles/NUT2012sa0228EN.pdf
5 Avis du Conseil Superieur de la Sante No 9312: Complements alimentaires a base de ‘levure de riz rouge’.
6 “Toxicological evaluation of red mould rice: un updated”, December 18th 2012, DFG Permanent Senate Commission on Food
Safety, Deutsche Forschungsgemeinschaft DFG.
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In the light of above opinions, Member States raised concerns during discussions on the possible
authorisation of the above-mentioned health claim, due to the potential risk for consumers linked with
the consumption of monacolin K from red yeast rice.
Consequently, the Commission has initiated the procedure under Article 8 (2) of Regulation (EC) No
1925/2006 on the addition of vitamins and minerals and of certain other substances to foods,7 for
monacolins from red rice.
1.1.2. Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20028, the European Commission
asks EFSA to:
• Review the existing scientiﬁc data on the possible link between the intake of monacolins from
red yeast rice and harmful effects on health.
• Provide advice on a dietary intake of monacolins from red yeast rice that does not give rise to
concerns about harmful effects to health, for the general population, and as appropriate, for
vulnerable subgroups of the population.
1.2. Interpretation of the Terms of Reference
In respect to the approach to be followed for the assessment of monacolins, the ANS Panel was of
the view that previous assessments, when relevant to the safety issues that triggered the Article 8
procedures, should be used as starting points for this scientiﬁc opinion.
Monacolin K has been speciﬁed as the food constituent in RYR preparations which is responsible for
the claimed effect on the maintenance of normal blood LDL-cholesterol concentrations. In assessing the
safety of monacolins, the Panel considered monacolin K and lovastatin identical, the latter being the
active ingredients of medicinal product authorised in the EU for the treatment of hypercholesterolaemia.
The Panel noted that in the health claim (EFSA NDA Panel, 2013), the intake of monacolin K is 10 mg/day
for the maintenance of normal blood LDL-cholesterol concentrations. This intake of monacolin K overlaps
the lowest therapeutic dose of 10 mg/day of lovastatin indicated as the starting dose for the treatment of
hypercholesterolaemia (SPC for lovastatin, online).
The effect of other possible ingredients of food supplements on monacolins bioactivity is not
considered in this opinion.
1.3. Deﬁnition and identiﬁcation of monacolins from red yeast rice
In its 2013 scientiﬁc opinion on the substantiation of health claims, the EFSA NDA Panel describe
monacolins as polyketides that are secondary metabolites produced by the fermentation of red rice
with the fungus M. purpureus.
Because monacolin K in lactone form is identical to lovastatin,9 data on the latter have also been
considered relevant for this opinion (see Figure 1).
7 OJ L 404, 30.12.2006, p. 26.
8 OJ. L 031, 1.2.2002, p. 1–24.
9 From Eu Pharmacopeia: (1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-
hexahydronaphthalen-1-yl (2S)-2-methylbutanoate.
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Although the Panel considered that the lactone form of monacolin K and lovastatin are identical
chemical substances, in the current opinion, the two terms ‘monacolin K’ and ‘lovastatin’ have been
used when referring to the compound present in RYR and the medicinal product, respectively (i.e.
whenever data were generated with RYR, the term monacolin K has been used, in the case of data
related to medicinal products, the term lovastatin has been used.
1.4. Data and methodologies
1.4.1. Data
The evaluation is based on the published scientiﬁc literature available up to May 2018, monographs
and risk assessment reports by national and international authorities and the data available following
the launch of a public ‘Call for data’.
1.4.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA Guidance on
transparency in the scientiﬁc aspects of risk assessment (EFSA, 2009) and following the relevant
existing guidance documents from the EFSA Scientiﬁc Committee.
The risk assessment was performed according to the EFSA Guidance on safety assessment of
botanicals and botanical preparations intended for use as ingredients in food supplements (EFSA
Scientiﬁc Committee, 2009).
1.5. Information on existing assessments
As speciﬁed in the Background (Section 1.1) the Superior Health Council of Belgium
(‘Documentation provided to EFSA’ n. 1), French Agency for Food, Environmental and Occupational
Health and Safety (ANSES) (‘Documentation provided to EFSA’ n. 2) and Joint Expert Committee of
Federal Ofﬁce of Consumer Protection and Food Safety (BVL) and the Federal Institute for Drugs and
Medical Devices (BfArM) (‘Documentation provided to EFSA’ n. 3 and 4) have also evaluated the safety
assessment of monacolins from RYR.
The Panel is also aware that RYR preparations containing monacolins have been evaluated by a
number of Committees or international organisations for their potential beneﬁcial effects and/or for
their potential adverse effects as food or as medicinal products (SKLM, 2012; Health Canada, 2014;
FDA, 2014; Chinese Ministry of Public Health, 2015).
1.5.1. European Food Safety Authority (EFSA)
In 2011 and 2013, the EFSA NDA Panel issued opinions on the substantiation of health claims
related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol
concentrations.
On the basis of the data available, the NDA Panel in both cases concluded that a cause and effect
relationship had been established between the consumption of monacolin K from RYR and
maintenance of normal blood LDL-cholesterol concentrations. According to the NDA Panel in order to
obtain the claimed effect, monacolin K from fermented RYR preparations should be consumed at the
intake of 10 mg/day. The consumption of monacolin K from RYR is intended in adult population only.
Figure 1: Chemical structures of monacolin K as a lactone (A) and its interconversion to monacolin K
hydroxy acid (B) in aqueous media
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In relation to restrictions of use, the NDA Panel referred to the SPC of lovastatin-containing medicinal
products available on the EU market (EFSA NDA Panel, 2011, 2013).
2. Technical data
2.1. Identity and nature of the source material
RYR is traditionally prepared by fermenting rice with the yeast, M. purpureus.
In response of a ‘Call for data’ interested parties submitted data on classiﬁcations of Monascus
purpureus and on the rice. However, the Panel considered that this information was incomplete
(‘Documentation provided to EFSA’ n. 5, 6, 9 and 11). Therefore, the Panel considered retrieving
information on the classiﬁcation of yeast and rice from relevant databases publicly available (Table 1).
The Panel noted that no information was provided by interested parties on species other than
M. purpureus used in the manufacturing of RYR.
2.2. Manufacturing process
Speciﬁc request for information on the manufacturing process used for the botanical ingredients
used in food supplements containing monacolin K was included in the ‘Call for data’ launched. The
information received was complemented by the Panel with data retrieved in the published literature.
According to interested parties, red yeast fermented rice is traditionally produced by cultivating the
yeast M. purpureus on rice. Rice is sterilised and then inoculated with a M. purpureus starter. A
fermentation process at controlled temperature follows for several days. No solvents are used during
the manufacturing process (‘Documentation provided to EFSA’ n. 5, 6, 7, 9, 10 and 11).
The rice is ﬁrst soaked in water until the grains reach a semi-gelatinous state. Inoculation is done
by adding a Monascus starter culture. The mix is then incubated and periodically stirred in a
temperature-controlled chamber for some days. During this period of time, the rice grains turn bright
red in their core and reddish purple on the outside (Chen et al., 2005).
Several modiﬁcations have been applied to the fermentation process (nitrogen source, pH,
temperature, water supply, etc.), which can modulate the resulting ﬁnal product in term of content in
monacolin K, pigments, citrinin, and other minor compounds (Chen et al., 2015a).
According to Zhang et al. (2000), the traditional approach allows the production of RYR derivatives
containing low level of monacolin K, while a patent from the same authors describes a new process
producing a RYR-based product with a content of monacolins of at least 0.005% and up to 2% (Zhang
et al., 2000).
It has been reported that Monascus purpureus strains (N301 and N310), which are characterised
by very high monacolin K and low citrinin production, have been selected and bred to allow
manufacture of RYR products on an industrial scale (Wang et al., 2004).
The strain of M. purpureus is critical for the levels of monacolins and citrinin measured in the ﬁnal
products (Chen and Hu, 2005), but also the fermentation processes and growing conditions (medium,
temperature) can contribute to the variability (Borresen et al., 2012; Chen et al., 2015a).
Table 1: Information related to the classiﬁcation of rice and yeast, as ingredient of RYR
Plant Yeast
Family Poaceae Monascaceae
Genus Oryza L. Monascus
Species Oryza sativa L. Monascus purpureus (Went 1895)
Variety –
Synonyms Red rice koji or Hongqu –
Part used Rice grain, rice kennel, fruit, seeds –
Geographical origin Hangzhou, China, Asia –
Growth and harvesting conditions Standard plain rice –
RYR: red yeast rice.
http://www.theplantlist.org/tpl1.1/record/kew-426698;
http://www.indexfungorum.org/Names/NamesRecord.asp?RecordID=235390;
http://www.gbif.org/species/5259748/classification
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2.3. RYR and traditional use
RYR is traditionally used in China as a food colour and for therapeutic purposes (Chinese Medical
Herbology and Pharmacology, 2004). It is produced by fermentation of a microscopic fungus grown on
cooked rice (Ma et al., 2000; NIH, 2015). Rice fermented in this way becomes red due to the presence
of fungal pigments. The fungus used for fermentation belongs to the class Ascomycetes, order
Eurotiales, family Monascaceae and genus Monascus. Traditionally prepared, RYR (Hung-ch’u, Hongqu,
Angkak or Beni Koji) is the product of fermentation deriving from a mixture of several species from the
genus Monascus, the main one being M. purpureus Went, discovered in 1895. The other species
producing similar fermentations are Monascus ruber van Tieghem, Monascus fuliginosus Sato,
Monascus pilosus Sato and Monascus albidus Sato (Zhang et al., 2000). Sixty-ﬁve strains are currently
deposited at the American Type Culture Collection (ATCC) belonging to three species: M. pilosus,
M. purpureus and M. ruber. Non-traditional RYR preparations are not currently on the market for their
uses as ingredients in food supplements (Hawksworth and Pitt, 1983; Lin et al., 2008; ANSES, 2014).
2.4. Chemical composition
2.4.1. Monacolins
Fungi from the genus Monascus produce several molecules called monacolins, among which
monacolin K is the most abundant (Ma et al., 2000). In RYR, the monacolin K (hydroxy acid) form is
also present (Figure 1). Monacolin K (lactone) and monacolin K (hydroxy acid) exist in equilibrium and
their ratio depends mainly on pH. At low pH, monacolin K lactone is the predominant form whereas at
neutral and basic conditions, the monacolin K hydroxy acid predominates. The lowest interconversion
rate was pH 4.5, there is (Nigovic et al., 2013; Mornar et al., 2013). The chemical structure of
monacolins identiﬁed in RYR is reported in the Appendix A.
According to Mornar et al. (2013), in most tested RYR samples, monacolin K lactone predominates
over the monacolin hydroxy acid.
According to information provided by an interested party following a Call for data, before drying,
RYR contains more than 80% monacolin K in its acid form. During drying (usually at 50–60°C), some
part of acid form loses a molecule of water and converts to the lactone form. The ﬁnal ratio between
acid form and lactone form after drying is usually between 6:4 and 3:7. Both forms of monacolin K
(lactone and hydroxy acid) remain stable over time. The lactone form represents approximatively 85%
of the total monacolin K content, and the acid form represent approximatively 15% of the total
content (‘Documentation provided to EFSA’ n. 11). The Panel noted that there is an inconsistency with
the ratio of lactone and acid forms in the information provided by one of the interested parties.
The Panel noted that in response of the public ‘Call for data’ launched by EFSA, no data on the
possible presence of monacolins other than monacolin K have been reported by interested parties.
On the basis of the information available in the literature, the Panel noted that different monacolins
have been identiﬁed in RYR samples. These molecules include monacolin J (lovastatin diol lactone),
monacolin L (the precursor of monacolin J), dehydromonacolin K (dehydrolovastatin), compactin
(mevastatin). Monacolin K and monacolin K hydroxyacidic forms represent approximately 50% and
25%, respectively, of total monacolins (Ma et al., 2000).
The Panel noted that there seems to be a discrepancy between the information retrieved through
the public call for data and the publicly available information from the literature with respect to the
occurrence of the chemical forms of monacolin K in RYR.
2.4.2. Other compounds present in RYR
Fatty acids
The fatty acids found in RYR (approximately 3%) can be classiﬁed in two groups:
• saturated fatty acids including palmitic, stearic and eicosanoic (arachidic) acids;
• unsaturated fatty acids including oleic, linoleic and linolenic acids (Ma et al., 2000).
Pigments
Six main pigments have been identiﬁed in RYR (Lin et al., 2008; Patakova, 2013; Chen et al., 2017)
they are secondary metabolites belonging to the family of azaphilones (Figure 2) and are classiﬁed
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according to their colour: rubropunctatin and monascorubrin are orange; monascin and ankaﬂavin are
yellow; and rubropunctamine and monascorubramine are red.
Their content in RYR is approximately 0.3% (Heber et al., 1999).
Citrinin
Under some conditions, Monascus strains produce a secondary toxic metabolite called citrinin, a
mycotoxin produced also by the genera Aspergillus and Penicillium (Liao et al., 2014). It may be
present in stored grain, as well as in other plant products such as beans, fruits, fruit or vegetable
juices, plants used for medicinal or condiment purposes, spices and tainted dairy products (EFSA
CONTAM Panel, 2012).
A tolerable daily intake (TDI) of 0.2 lg/kg body weight (bw) per day has been set by the CONTAM
Panel for citrinin.
In response of the ‘Call for data’ launched by EFSA, interested parties provided analytical data on
the occurrence of citrinin in food supplements containing monacolin K from RYR that were in
compliance with the maximum permitted level of 2 mg/Kg in accordance to the Commission Regulation
(EU) No 212/2014 (‘Documentation provided to EFSA’ n. 5, 6, 7, 9, 10 and 11).
Other
RYR also contains other components: starch (73.4%), proteins (5.8%), ﬁbres (0.8%), minerals
(phosphorus, sodium, calcium, iron, magnesium, aluminium, manganese, copper, silver) (Heber et al.,
1999; Li et al., 2004). RYR contains sterols, such as b-sitosterol, campesterol, stigmasterol and
sapogenine (Heber et al., 1999).
2.4.3. Content of monacolins in RYR and sources of variability
According to data reported by several authors, the amounts of monacolins in food supplements
containing RYR can vary signiﬁcantly. Gordon et al. (2010) quantiﬁed monacolins and citrinin in 12 RYR
food supplements available in the US market. The Panel noted variability both in monacolins and
citrinin concentrations (Table 2). However for the latter, no exceedance of the established limit in EU
(2 mg/kg) was reported.
Figure 2: Chemical structures of RYR pigments (modiﬁed from Lin et al., 2008). a = rubropunctatin
(orange); b = monascorubrin (orange); c = monascin (yellow); d = ankaﬂavin (yellow); e =
rubropunctamine (red); f = monascorubramine (red)
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Table 2: Levels of monacolins in 12 commercial products available in the US market (Gordon et al., 2010)
Product
Daily
intake
Total
monacolins
MK MKA MKA/
MK
MJ MJA MX MXA ML MLA MM MMA DMK Citrinin
Capsule mg/600 mg-capsule lg/600 mg-capsule
A 4 5.3 2.53 1.96 0.77 4 27 76 59 122 19 29 NT 473 0
B 4 2.16 1.02 0.61 0.59 19 12 0 8 55 80 7 NT 212 0
C 1–2 4.18 1.74 1.63 0.93 32 49 108 24 67 33 18 73 281 0
D 2 1.65 1.12 0.22 0.19 0 13 55 0 49 11 0 0 140 14.3
E 4 6.03 3.63 1.22 0.33 31 169 125 18 88 85 64 31 386 0
F 2 0.31 0.1 0 0 0 0 0 0 0 0 0 160 51 114.2
G 4 6.18 2.5 2.3 0.92 43 54 104 20 36 49 19 51 929 0
H 1 11.15 10.09 0.52 0.05 0 58 73 0 43 38 45 71 141 0
I 2 1.60 0.99 0.23 0.23 0 0 0 0 42 0 210 0 93 57.5
J 2 3.97 2.66 0.46 0.17 0 25 98 0 126 53 88 41 305 0
K 2 1.36 0.97 0.19 0.19 0 14 0 0 39 0 0 0 110 70.4
L 2–4 6.13 3.12 2.07 0.66 42 64 112 16 56 83 59 19 315 0
m  SD 4.17  3.00 2.54  2.60 0.95  0.84 14  18 40  46 63  49 12  17 60  36 38  33 40  59 45  49 286  239 21.4  38.2
Median 4.08 2.12 0.57 20 26 75 4 52 36 24 36 246 0
MK: monacolin K; MKA: monacolin K hydroxyacid; MJ: monacolin J; MJA: monacolin J hydroxyacid; MX: monacolin X; MXA: monacolin X hydroxyacid; ML: monacolin L; MLA: monacolin L
hydroxyacid; MM: monacolin M; MMA: monacolin M hydroxyacid; DMK: dehydroxymonacolin K.
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Klimek et al. (2009) reported the content of monacolin K, monacolin L and citrinin in nine RYR
products recommended for hyperlipidaemia (Table 3). The composition of the unit (capsule) and daily
intake were not reported, however no information was available on the weight of the capsule.
Avula et al. (2014) reported the content of monacolin K in 14 commercial food supplements
analysed by liquid chromatography coupled with mass spectrometry: monacolin K content ranged
between 0.03 and 2.18 mg and between 0.22 and 5.23 mg in products containing 600 and 1,200 mg
of RYR, respectively.
Cohen et al. (2017), analysed monacolin K level in 28 brands of food supplements by ultrahigh-
performance liquid chromatography-diode array detector quadrupole time-of-ﬂight mass spectrometry.
Two samples did not contain monacolin K; in the remaining supplements, monacolin K concentrations
ranged between 0.05 and 2.74 mg per 600 mg of RYR. According to the serving reported in the label,
the amount of monacolin K consumed daily ranged between 0.09 and 10.94 mg.
Li et al. (2004) described the content of monacolins and compactin in 10 commercial products
containing RYR; no information on RYR content or daily intake was reported (Table 4).
The Panel noted that there is a large variability and discrepancy in both the content of monacolin K
and the ratio between monacolin K lactone and its hydroxyacid form in the 10 commercial products
considered (Table 4). Some samples showed a clear predominance of monacolin K lactone, which
seems not usual in natural RYR products (see ratio in RYR powder (RYRP)).
Table 3: Contents of monacolins and citrinin in nine Chinese RYR products sold in US market
(Klimek et al., 2009)
RYR supplements
Monacolin K
(mg/capsule)
Monacolin L
(mg/capsule)
Citrinin
(lg/capsule)
Cholesterex 1.35 < 0.006 4.87
Cholestene 2.87 < 0.006 2.22
Cholactive 1.80 < 0.006 6.06
Cholester-Reg 3.37 < 0.006 3.23
Beyond cholesterol 0.15 0.02 Not available
Hongqu 2.86 < 0.005 11.82
Cholesterol power 2.51 < 0.007 0.47
Red yeast rice 1.56 < 0.006 64.7
Cholestin 2.46 0.015 Not available
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Table 4: Level of monacolins in 10 commercial products (Li et al., 2004)
Product Reference Total monacolins MK MKA
MKA/
MK
MJ MJA MX MXA ML MLA MM MMA DMK PI
RYRP lg/g 622.65 362.37 103.23 0.28 12.64 7.08 4.74 3.64 23.32 15.36 5.19 0.72 72.22 12.14
CP1 lg/capsule 307.08 302.48 3.57 0.01 ND ND ND ND ND ND ND ND 1.03 ND
CP2 lg/capsule 98.20 93.65 2.81 0.03 ND ND ND ND ND ND ND ND 1.74 ND
CP3 lg/capsule 142.34 112.76 6.9 0.06 ND ND ND ND ND ND ND ND 22.98 ND
CP4 lg/capsule 135.68 126.61 3.44 0.03 ND ND ND ND ND ND ND ND 5.63 ND
CP5 lg/tablet 17.27 10.52 6.75 0.64 ND ND ND ND ND ND ND ND ND ND
CP6 lg/tablet 13.91 ND 12.8 ND ND 1.11 ND ND ND ND ND ND ND ND
CP7 lg/tablet 155.68 112.00 19.60 0.18 ND ND ND ND 4.48 ND 0.91 ND 15.05 1.75
CP8 lg/capsule 18.69 34.19 11.55 0.34 ND ND ND ND ND ND ND ND 7.14 ND
CP9 lg/capsule 357.76 198.65 63.48 0.32 7.22 4.33 2.75 2.08 13.47 8.86 3.01 0.44 46.5 6.97
CP10 lg/tablet 461.56 259.32 82.66 0.32 8.56 3.62 2.94 3.12 18.46 9.23 3.22 0.52 59.68 8.23
Average(a) lg/unit 170.82 138.91 21.36 0.15 15.98 ND
St Dev(a) 155.25 97.39 28.10 21.11 ND
Median(a) lg/unit 139.01 119.68 9.23 6.39 ND
RYRP: RYR powder; CP: Commercial product: MK: monacolin K; MKA: monacolin K acid form; MJA: monacolin J acid form; MJ: monacolin J; MXA: monacolin X acid form; MLA: monacolin L acid
form; MX: monacolin X; ML: monacolin L; MMA: monacolin M acid form; MM: monacolin M; DMK: dehydroxymonacolin K; PI: compactin, ND: not detectable.
Products C1–C6 were from US store market; C7 and C8 from Taiwan; and C9 and C10 from China marketing.
(a): Calculated by the Panel on CP values, where ND was considered 0.01.
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The Panel calculated the mean, SD and the median of the monacolin K contents and recommended
daily intake of 26 food supplements containing RYR where monacolin K was detectable and marketed
in the US (as reported by Cohen et al., 2017). The Panel noted that no information was provided on
monacolin K hydroxy acid form. The mean monacolin K contents of food supplements containing RYR
(m  SD) was 1.22  1.85 mg/600 mg RYR, ranging between 0.05 and 2.74 mg/600 mg; the
recommended daily intake 2.42.88 mg/day (mSD), ranging between 0.09 and 10.94 mg/day. The
medians were 0.92 mg/600 mg RYR and 1.23 mg/day, respectively.
Chen and Hu (2005) evaluated the production of monacolin K and citrinin by 29 Monascus strains:
the concentrations in RYR ranged between <0.08 and 0.22 mg/g, and between <40 and >1,000 ng/g,
respectively.
The Panel noted that information on the presence of monacolins other than monacolin K was
included in some of the studies described above (Li et al., 2004; Klimek et al., 2009; Gordon et al.,
2010). Furthermore, the Panel noted that in some cases the recommended daily intake of monacolin K
in food supplements as reported in the studies, overlap the therapeutic dose (10 mg/day) (Gordon
et al., 2010; Cohen et al., 2017). However, in other cases, the recommended daily intakes of
monacolin K or of RYR are not reported by the authors ( Li et al., 2004; Klimek et al., 2009).
2..5. Speciﬁcations
There are no speciﬁcations for RYR used as food including food supplements in EU Regulations. No
speciﬁcations for RYR were found on European, Japanese, Canadian, US Pharmacopeia or in the WHO
monographs.
The Panel noted that speciﬁcations exist for lovastatin in the EU Pharmacopeia when used as a
medicinal product.
On the basis of the information gathered from the relevant food sector operators following the
launch of a public ‘Call for data’, the Panel was made aware of certain maximum levels for
contaminants and of results of microbiological analysis that are applicable to the food supplements
containing monacolin K from RYR (‘Documentation provided to EFSA’ n. 5, 6, 7, 9 and 11).
2.6. Stability of the botanical or botanical preparation used as
ingredients in food supplements
Speciﬁc request for information on the stability of botanical ingredients used in food supplements
containing monacolin K was included in the ‘Call for data’ launched. The information received was
complemented by the Panel with data retrieved in the published literature. The Panel noted that most of
the interested parties provided stability data on the ﬁnal products rather than on the botanical
ingredients. According to data submitted by one interested party, the monacolin K content is stable over
a period of 2 years (‘Documentation provided to EFSA’ n. 7).
In the scientiﬁc literature, there are only few studies reporting the effects of storage on the levels
of monacolins in RYR-based products. Lin et al. (2005) performed a study using accelerated storage
conditions, where the role of temperature, humidity and sunlight exposure on RYR preparations was
assessed.
The results of testing the stability under the accelerated storage conditions of 40°C and 75%
relative humidity are given in Table 5.
Table 5: Changes in monacolins levels (mg/g) in RYR during an accelerated testing at 40°C and
75% of relative humidity(a)
Molecule Day 0 Day 10 Day 30 Day 90
Changes at
90 days (%)
Monacolin K hydroxy acid 1.048 1.055 1.064 1.092 +4.2
Monacolin K 3.351 3.223 3.128 3.006 10.3
Dehydromonacolin K 0.493 0.494 0.49 0.481 2.4
Total monacolins 5.326 5.212 5.125 5.021 5.9
(a): Modiﬁed from Lin et al. (2005).
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2.7. Use and use levels
2.7.1. Content of monacolins in RYR products as provided by interested parties
following the launch of a public ‘Call for data’
In October 2017, a request was sent to relevant business operators, asking for information on
recommended daily intake of food supplements containing monacolins (monacolin K) from RYR.
On the basis of the data received, the Panel noted that the recommended daily intake of monacolin
K from RYR ranges from 9 to 20 mg (‘Documentation provided to EFSA’ n. 5, 6, 8, 9 and 10). The
Panel further noted that the recommended daily intake of 20 mg of monacolin K is reported for one
product only that according to the interested party is planned to be delisted.
The Panel noted that no data were provided on the occurrence levels of other monacolins in RYR.
Summarised data extracted from the Mintel GNPD
The Mintel Global New Products Database (Mintel GNPD) is an online database which monitors
product introductions in consumer packaged goods markets worldwide. It contains information of over
2 million food and beverage products of which more than 800,000 are or have been available on the
food market of the Member States. Mintel started covering the EU countries’ food markets in 1996,
currently having 20 out of its 28 member countries presented in the Mintel GNPD.
For the purpose of this Scientiﬁc Opinion, the Mintel GNPD was used for checking the labelling of
products containing monacolin K from RYR within the EU countries’ food products as the Mintel GNPD
shows the compulsory ingredient information presented in the labelling of products. According to the
Mintel GNPD, monacolin K was labelled on 40 products between January 2012 and February 2018. The
food category considered was: ‘Vitamins & Dietary Supplements’. The concentrations of monacolin K
were also retrieved from this database, when available. In all these products, the content of monacolin
K was clearly stated.
The daily consumption in terms of monacolin k for each product was calculated by multiplying the
intake unit of monacolin K by the daily number of recommended intakes of the product. The daily
intake of monacolin K for these products ranged from 2 to 48 mg/day, for adult population (Table 6).
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Table 6: Summary of data on food supplements containing RYR, collected by consulting MINTEL GNPD
Country No. of products
Intake of monacolin K (mg/day)
Comments
Mean  SD Median Range
Austria 1 10 10 10 One product at 10 mg/day
Croatia 4 10 10 10 Four products all at 10 mg/day
Czech Rep. 1 3 3 3 One product at 3 mg/day
Finland 1 10 10 10 One product at 10 mg/day
France 10 10.5  13.6 7.45 2–48 Wide range of daily intake
Germany 2 7.1 4–10.2
Ireland 1 10 10 10 One product at 10 mg/day
Italy 9 6.1  3.7 3 3–10 Five products at 3 mg/day; four products at 10 mg/day
Netherland 5 10.5  6.2 10 2.6–20 Three products at 10 mg/day
Spain 4 8.6  3.7 10.2 3–10.9 Three products at values close to 10 mg/day
UK 2 10 10 10
Total 40 10.5  6.2 10 2–48 More than 50% at values close to 10 mg/day
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The Panel noted that the number of RYR products retrieved from the Mintel GNPD is only a part of
those on the European market. However, the Panel considered that it would be possible to draw
sufﬁciently reliable conclusions on the average intake of monacolin K according to the recommended
daily intake reported on the label. The recommended daily intakes range between 2 and 48 mg of
monacolin K, but the majority of food supplements (around 25%) supplies a recommended daily
intake of 10 mg according to the level established by EFSA for supporting the health claim (EFSA NDA
Panel, 2013). The Panel noted that only 8 out of 40 products were mono-ingredient, containing only
RYR preparation; in the remaining 32 products the most frequently associated ingredients were:
artichoke extract, berberine (Berberis aristata), coenzyme Q10, chromium, policosanol, resveratrol and
vitamins.
On the basis of the information retrieved from the Mintel GNPD database, the Panel noted that two
products reported recommended a daily intake of 20 or 48 mg of monacolin K.
3. Biological and toxicological data
3.1. Preclinical studies
3.1.1. Lovastatin
The Panel considered that information included in the SPC, based on the assessments performed by
regulatory authorities for medicinal products containing lovastatin, is current and relevant for this
assessment.
The Panel noted data from preclinical studies are reported in the SPCs for lovastatin tablets (SPC,
online). While genotoxicity studies in vitro and in vivo did not indicate a genotoxic potential, results of
long-term studies (21 months) involving oral administration of lovastatin at 500 mg/kg bw per day in mice
revealed an increase in tumour incidences (e.g. hepatocellular carcinomas and adenomas) (TOXNET,
online).10 According to the SPC, the relevance of this data for the risk assessment in humans is unclear.
Fetal skeletal malformations have been described in rodents following exposure to high doses (800
mg/kg bw per day) and impaired fertility has been observed in dogs at doses of 20 mg/kg bw per day
and above (MacDonald and Halleck, 2004; SPC, online).
The Panel considered that the available preclinical data do not allow to derive a safe intake for
monacolins in RYR.
3.1.2. Other compounds
Several biological activities were associated with the RYR pigments in in vitro studies: antifungal,
antiviral, antioxidant, cytotoxic, nematicidal and anti-inﬂammatory (Osmanova et al. 2010). Moreover,
a RYR fraction containing only red Monascus pigments was associated with the induction of cellular
senescence of highly proliferating HepG2 cancer cells (Wei and Popovich, 2013). In 3-day-old chicken
embryos, incubation at 38.5°C for 9 days with the pigments monascorubrin, rubropunctatin, monascin
and ankaﬂavin, which were puriﬁed from the mycelium of M. purpureus, led to malformations
and lethality. From the sum of dead and malformed embryos, the ED50 (dose causing these effects
in 50% of the embryos) were calculated. The means ED50 were 4.3 lg/embryo, 8.3 lg/embryo,
9.7 lg/embryo and 28 lg/embryo, respectively (Martınkova et al., 1999).
Citrinin is hepatotoxic and nephrotoxic in different animal species and in humans (EFSA CONTAM
Panel, 2012). Citrinin as such did not show mutagenic activity in the Ames test, but hepatocyte-derived
metabolites were positive in this test (Sabater-Vilar et al., 1999; Patakova, 2013).
3.2. Pharmacology
3.2.1. Statins
The therapy with statins is aimed at reducing the level of circulating cholesterol in subjects
suffering from dyslipidaemia, who are at risk for cardiovascular diseases. The target of statins is the
enzyme 3-hydroxy-3 methylglutaryl-coenzyme A (HMG-CoA) reductase (EC 1.1.1.34), which converts
HMG-CoA into mevalonate, the precursor of cholesterol. The site of statin action is shown in Figure 3
(Rotta Bonﬁm et al., 2015).
10 https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/f?./temp/~2vtEOb:3
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Statins reduce the cellular cholesterol concentration through two different mechanisms: (1) the
inhibition of the enzyme HMG-CoA reductase with the associated reduction of cholesterol biosynthesis,
and (2) the reduction of cholesterol concentration in liver. As a consequence, there is an increase of
the expression of LDL-receptors in hepatic cell membranes, producing a more efﬁcient clearance of
LDL-cholesterol from blood (Stancu and Sima, 2001; Schachter, 2004; Sirtori, 2014).
Lovastatin hydroxy acid shows its inhibitory activity on HMG-CoA reductase both in humans and
other animal species (Goswami et al., 2012).
3.2.2. Dose range for pharmacological effect of lovastatin
According to the SPC of medicinal products containing lovastatin as an active ingredient, the
recommended therapeutic dose of lovastatin for the treatment of hypercholesterolaemia ranges
between 10 and 80 mg/day, where the dose of 10 mg/day is mainly considered as the starting dose.
3.2.3. RYR and monacolin K
Effects on cholesterolaemia
Most clinical studies performed with RYR focused on the cholesterolemia reduction and, in
particular, of the serum concentration of total cholesterol (TC) and LDL-cholesterol (LDL-C).
There are some trials where RYR mono-ingredient products were used (Heber et al., 1999; Lin
et al., 2005; Burke, 2015).; two of them were considered in the EFSA opinion (Heber et al., 1999; Lin
et al., 2005 cited in EFSA NDA Panel, 2011).
In 2014, Li and co-workers published a meta-analysis collecting clinical data on the effects and
safety of RYR (Li et al., 2014). Considering all the papers describing clinical studies published at that
time in PubMed, Cochrane Library, EBSCO and other databases, the authors selected 13 papers, which
were considered relevant. These publications were selected considering, as an inclusion factor, the
quality of clinical studies so that most of them were randomised, placebo-controlled trials. All papers
reported data of cholesterolemia before and after the consumption of products containing RYR. The
Panel noted that only in 4 out of 13 trials, RYR was the only ingredient of the products received by the
intervention group. For these reasons, only the clinical studies where the supplementation was based
on mono-ingredient products will be considered in this opinion (Table 5). The paper by Lin et al.
(2005) is not included in the meta-analysis by Li et al. (2014) but it is added in the table since it was
reported by EFSA in its opinion on the ‘health claim related to the effect of monacolin K from RYR on
the maintenance of normal blood cholesterolemia’ (EFSA NDA Panel, 2011). Another more recent
study, also included in Table 5, demonstrated that also an intake dose of 3 mg of monacolin K from
Figure 3: Biosynthetic pathway of cholesterol and statin target (Rotta Bonﬁm et al., 2015)
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RYR (with 200 lg of folic acid) is active in reducing signiﬁcantly the level of total cholesterol and LDL-
cholesterol (Heinz et al., 2016).
All studies were randomised, double-blind and placebo-controlled; the dose used ranged from 200
to 3,600 mg of RYR, corresponding to 3–11.4 mg of monacolin K; the trials lasted from 8 to 16 weeks.
Data are summarised in Table 7.
The reduction in total cholesterolaemia and LDL-cholesterolaemia showed a dose-dependent trend.
The treatment for 8 weeks with the highest dose was sufﬁcient to reach the mean reduction of 20% in
both total and LDL-cholesterol. Longer periods (12–24 months) were necessary to obtain statistically
signiﬁcant reduction of total and LDL-cholesterol at the lowest doses (3–6.12 mg) of monacolin K.
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Table 7: Changes in total cholesterol and LDL-Cholesterol reported in controlled studies where RYR was the only treatment to reduce
hypercholesterolaemia (modiﬁed from Li et al., 2014)
Reference
Type of study
(period)
Number of
patients
Sex age
Daily intake of RYR
(monacolin K)
Total cholesterol
in RYR group
LDL-Cholesterol
in RYR group
Change
(%)
Statistical
signiﬁcance vs
placebo
Change
(%)
Statistical
signiﬁcance vs
placebo
Heinz et al. (2016(b)) R, DB, PC (12 weeks) C = 72
T = 70
M/F
18–70 years
200 mg (3 mg) 11.2 p < 0.001 14.8 p < 0.001
Becker et al. (2009) R, PC (24 weeks) C = 31
T = 31
M/F
21–80 years
3,600 mg (6.12 mg) 14.9 p < 0.016 21.3 p < 0.011
Bogsrud et al. (2010) R, DB, PC (16 weeks) C = 22
T = 20
M/F
18–75 years
1,200 mg (7.2 mg) 15.0 p < 0.001 23.0 p < 0.001
Heber et al. (1999(a)) R, DB, PC (12 weeks) C = 41
T = 42
M/F
34–78 years
2,400 mg (7.2 mg) 16.1 p < 0.05 21.9 p < 0.05
Huang et al. (2007) R, DB, PC (8 weeks) C = 40
T = 39
M/F
18–65 years
1,200 mg
(11.4 mg)
20.4 p < 0.001 26.3 p < 0.001
Lin et al. (2005(c)) R, DB, PC (8 weeks) C = 38
T = 37
M/F
23–65 years
1,200 mg (11.4 mg) 20.4 p < 0.001 26.3 p < 0.001
R: Randomised; DB: Double Blind; PC: Placebo Controlled; C: control group; T: Intervention group.
(a): Included also in EFSA NDA Panel (2011).
(b): Not included in Li et al. (2014) and EFSA NDA Panel (2011).
(c): Included in EFSA NDA Panel (2011) but not in Li et al. (2014).
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The Panel noted that the data from the clinical trials above show a dose-dependent pattern.
3.3. Absorption, distribution, metabolism and excretion (ADME)
3.3.1. Lovastatin
Lovastatin is a lactone prodrug that is converted by esterases to its active form, lovastatin hydroxy
acid (HA) which inhibits the enzyme HMG-CoA reductase, the rate-limiting enzyme in the cholesterol
biosynthetic pathway in the liver (Alberts et al., 1980). These esterases, also known as lactonases, are
known to be present in the plasma and liver and according to pH, to catalyse also lactonisation of the
corresponding HAs (Fishbein et al., 1966). Due to this extensive ﬁrst-pass metabolism and its low
solubility (1.3 g/mL in water, Serajuddin et al., 1991), whereas the absorption is about 30%, intact
lovastatin exhibits a poor oral absolute bioavailability (< 5%) due to the CYP3A4 dependent high ﬁrst
pass (Schachter, 2004).
3.3.1.1. In vitro studies
Greenspan et al. (1988) investigated the hepatic metabolism of lovastatin and lovastatin HA, by
using rat and human liver microsomes. In human liver samples, the conversion of lovastatin to its
3- and 6-hydroxy derivatives was observed. No differences were observed between the microsomes
derived from males and females. The open acid form of lovastatin was not metabolised by the human
microsomes, as observed with rat liver microsomes.
Similar results were obtained by Vyas et al. (1990a) using rat and mice liver microsomes.
Microsomal metabolites were described to be active inhibitors of HMG-CoA reductase and their relative
enzyme inhibitory activities were 1, 0.6, 0.5 and 0.15 for the hydroxy acid forms of lovastatin, 60-b-
hydroxy-, 60-exomethylene- and 3″-hydroxy-lovastatin, respectively (Figure 4). In another study, Vyas
et al. (1990b) conﬁrmed that hydroxylation at the 60-position was the major pathway of lovastatin
biotransformation in human liver microsomes, whereas hydroxylation at the 3″-position of the side
chain was a minor pathway. The conversion of lovastatin to an additional 60-exomethylene metabolite
was shown to be catalysed by cytochrome P450.
Wang et al. (1991) reported that using human liver microsomes, that both anti-rat P450 3A and
anti-human P450 3A antibodies inhibited lovastatin metabolism (formation of 60-beta-hydroxy-,
60-exomethylene- and 3″-hydroxy-lovastatin). There was a correlation between lovastatin oxidation and
the P450 3A content in human liver microsomes. In addition, preincubation of human liver microsomes
with the suicide substrate troleandomycin and NADPH inhibited lovastatin metabolism by 60%. These
results clearly indicate that cytochrome P450 3A enzymes are primarily responsible for the oxidative
metabolism of lovastatin in rat and human liver microsomes.
3.3.1.2. In vivo studies
In rat, dog, monkey and human studies, Duggan et al. (1989) used 14C-lovastatin labelled on the
methylbutyryl side chain, or its acid metabolite 14C-HA prepared by hydrolysis of lovastatin at pH 11.
In all animal studies, intravenous and oral doses were 0.8 and at 8.0 mg/kg, respectively. Human
doses were 100 mg lovastatin given as a capsule or 40 mg HA infused over 120 min. In dog and
human plasma, the bioavailable (albumin-free) fraction of HA (4–4.6%) was about twice that of
lovastatin (1.4–1.8%) at pharmacologically relevant concentrations. Lovastatin was absorbed to a
lower extent in rats and dogs compared to the same dose of lovastatin acid (HA) given per se, but the
absorbed fraction reached the portal circulation largely unchanged and was more efﬁciently extracted
by the liver. In the liver, lovastatin was reversibly transformed to HA and irreversibly to other
biologically active metabolites. Metabolites such as HA, were maintained at high hepatic levels when
compared to all tissues examined in the rat. According to the authors, the low systemic levels of HA
are attributable in part to the metabolic equilibrium, lovastatin/HA equilibrium, the opposing reactions
for which appeared to be present in most tissues. In rats, dogs, monkeys and humans, urinary and
faecal recoveries of total radioactivity were measured over 4 days after either oral or intravenous
doses of radiolabelled lovastatin or HA. Following oral administration of lovastatin in humans, 9.6%
and 83.2% of the administered radioactivity were excreted in urine and faeces, respectively. Similar
results were obtained in dogs and monkeys. The excretion was largely biliary as measured in rats and
dogs. The authors concluded that comparisons of ADME proﬁles presented in their study indicate the
dog as the most appropriate animal model for studying human lovastatin bioavailability.
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Similar results were reported by Halpin et al. (1993) investigating differences in the in vivo
disposition of lovastatin (same radiolabelled material as used in Duggan et al. 1989) in mouse, rat, dog
and human. Lovastatin underwent extensive and complex metabolism in animals and humans, with the
metabolites excreted predominantly in bile. Radiochromatograms of bile from three human subjects
and of bile and liver homogenates from mouse, rat and dog indicated species differences in
metabolism. Three major metabolic pathways of lovastatin were described: hydrolysis of the lactone
ring to yield the pharmacologically active HA, cytochrome P450-mediated oxidation of the fused-ring
system, and beta-oxidation of the dihydroxy acid side chain. The ﬁrst two reactions occurred in all four
species, but the last one was observed only in mouse and rat. Human bile contained predominantly
polar metabolites. According to the authors, cytochrome P450 oxidation is the primary route of phase I
metabolism for lovastatin in human and dog whereas beta-oxidation plays a major role in rodents.
Additional pharmacokinetic data of lovastatin in man were reported in the review of Schachter
(2004). The conclusion by the Authors was that lovastatin has a short elimination half-life of 3 h,
whereas it is more effectively absorbed when taken with food. This is in line with the indication that
lovastatin tablets should be given with meals, as it increases lovastatin by 30–50% when taken with a
standard meal (Schmidt and Dalhoff, 2002). Moreover, due to the involvement of the CYP3A4 isoform
in its metabolism, the authors concluded that could be a risk for interactions between drugs that are
metabolised or inhibit CYP450, resulting in increased plasma levels of statins and possible consequent
increased risk of toxic effects.
Statins including lovastatin are usually administered as oral formulations; their absorption from the
small and large intestine depends on several parameters (dose, dissolution rate, intestinal transit and
absorption across the intestinal mucosa, etc.). In humans up to 31% of the dose is absorbed. Intact
lovastatin exhibits a low systemic bioavailability of 5% due to the CYP3A4 dependent high ﬁrst pass.
Both lovastatin and lovastatin HA are bound to human plasma proteins. When lovastatin enters the
enterocytes, it is metabolised by different enzyme systems, which are more abundant in small intestine
(Lennern€as and Fager, 1997).
According to the information reported in the SPC for medicinal product containing lovastatin, ‘It is
not known whether lovastatin or its metabolites are excreted into breast milk. As many drugs are
Figure 4: Major liver metabolic pathways of lovastatin in humans (from Wang et al., 1991)
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excreted into breast milk, and as there is a potential risk of serious undesirable effects, women taking
lovastatin should not breast-feed’ (SPC, online).
Moreover, ‘on the basis of results from animal studies, lovastatin crosses the blood/brain barrier and
the placental barrier’ (SPC, online).
3.3.2. RYR and Monacolin K
Li et al. (2005) compared the pharmacokinetics of a Chinese red yeast rice preparation (CRYR) with
lovastatin. CRYR is a botanical dietary supplement consisting mainly of rice, and by-products of
fermentation. The complete composition of this preparation was provided. The most abundant
ingredient was starch, constituting over 73% of the bulk and the protein content was 6%. Total
monacolins content corresponded to 0.4% of the preparation. Eleven healthy volunteers were
randomised to a crossover study taking either 20 mg of lovastatin or 2,400 mg CRYR (corresponding
to 4.6 mg monacolin K). In both arms, the participants received 200 mL of ‘double-strength grapefruit
juice’ three times/day for 2 days prior to the treatment; on the third day, treatments were
administered with 200 mL of the same juice. The Panel noted that the simultaneous administration of
grapefruit juice with lovastatin has been described to inhibit CYP3A4, and hence in this study, there
may have been a limitation in the presystemic elimination of lovastatin. Lovastatin and lovastatin acid
(HA) were measured in plasma of volunteers by a high-performance liquid chromatography with
tandem mass spectrometry (HPLC–MS/MS) method. When lovastatin was administered, Cmax were
23.67 and 40.94 ng/mL for lovastatin and HA, respectively. Following administration of CRYR, the
corresponding values were 1.25 and 4.31 ng/mL, respectively. Comparisons of area under the curves
(AUCs) demonstrated that AUC of lovastatin was 26-fold higher after lovastatin administration,
whereas AUC of HA was 9.7-fold higher after administration of lovastatin by comparison to the intake
of CRYR preparation. As reported in the paper, after normalisation for dose, the AUC of lovastatin was
calculated to be 7.21 greater than that of CRYR. According to the authors, this study demonstrated
that plasma concentrations of lovastatin and lovastatin hydroxy acid are much higher after ingestion of
lovastatin than of CRYR. The mixture of monacolins and other substances present in the RYR may
have some inhibitory effect on cholesterol biosynthesis. Moreover, in the current study, the lovastatin
to HA ratio of AUC was 1.72 for lovastatin and 3.48 for CRYR, which could suggest possible differences
in metabolism between the two modes of administration. Overall, these results would suggest that the
effect of CRYR on the cholesterol concentration might be caused by the additive and/or synergistic
effects of monacolin K with other monacolins and substances present in CRYR.
Chen et al. (2013) compared the dissolution rate, physical state and oral bioavailability in humans
of lovastatin in three RYR products (LipoCol Forte, Cholestin or Xuezhikang) to those of two lovastatin
tablets (Mevacor or Lovasta) (Chen et al., 2013). According to the authors, the dissolution rate of
lovastatin in various dissolution media in the registered RYR products was faster and higher than that
of lovastatin tablets. Powder X-ray diffraction and differential scanning calorimetry patterns showed
that the crystallinity of lovastatin was reduced in RYR products. In a ﬁrst human pharmacokinetic
study, a single intake of either four LipoCol Forte capsules (22.8 mg of monacolin K) and one Mevacor
tablet (20 mg of lovastatin) were compared in 14 volunteers. The results showed that plasma levels of
lovastatin and lovastatin hydroxy acid were signiﬁcantly higher in subjects given the LipoCol Forte
capsules. In these subjects, increases in AUC and Cmax values for both lovastatin (203% and 345%,
respectively) and lovastatin HA (366% and 515%, respectively) were observed by comparison to
corresponding data obtained in volunteers receiving lovastatin tablets. Shorter and less variable Tmax
values were also observed in the volunteers taking LopoCol Forte capsules. In a second
pharmacokinetic study (12 volunteers), 2,400 mg of powder from four LipoCol Forte capsules (22.8 mg
of lovastatin) and the powder from one ground Lovasta tablet (20 mg of lovastatin) were used in
order to reduce the effect of disintegration. In subjects taking LipoCol Forte powder, plasma
concentration, Cmax and AUC for both lovastatin and lovastatin acid were also signiﬁcantly higher (AUC
increased by 1.9 and 6.2 fold, respectively) than in those taking the Lovasta tablet powder. According
to the authors, the results of this study suggest that (1) the formulation of lovastatin (intact tablet vs.
ground tablet) is not an important factor in differences between pharmacokinetic properties of
lovastatin and lovastatin HA in RYR products compared to lovastatin tablets, (2) absorption rate and
systemic exposure of lovastatin are both increased in RYR products, (3) the oral bioavailability of
lovastatin is signiﬁcantly improved in RYR products as a result of a higher dissolution rate and reduced
crystallinity. In this paper, the authors discussed the differences in pharmacokinetic data when
compared to those obtained by Li et al. (2005). For them, lower serum lovastatin levels described
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following CRYR preparation would be attributable to the simultaneous intake of lovastatin or CRYR with
grapefruit juice, a well-known CYP3A4 inhibitor. This could signiﬁcantly increase plasma levels of
lovastatin and HA as demonstrated by Kantola et al. (1998) and ‘the results may not truly reﬂect the
pharmacokinetic properties of lovastatin in RYR products’.
The Panel noted as suggested by Chen et al. (2013) that differences observed in the plasma
concentration of lovastatin (and lovastatin HA) from RYR and the conventional medicinal product is
possibly due to the difference between the dissolution rates of the two formulations. The Panel further
noted that the complete composition of RYR extract used by Chen et al. (2013) was not provided,
particularly regarding the possible presence of other monacolins. From these studies, the
Panel considered that divergent data could be obtained in the pharmacokinetics of lovastatin and
lovastatin acid when RYR extracts or preparations are administered to humans.
3.3.2.1. Metabolic interaction between monacolin K from RYR with medicinal products or
foods
An interaction between a preparation containing RYR and cyclosporine was postulated in a 28-year
old kidney transplantation female patient (Prasad et al., 2002). This patient received several drugs in
the post-transplant period and developed rhabdomyolysis several months after starting the use of RYR.
The muscle disorder reversed when the intake of RYR product was ceased. The authors hypothesised
that the bioavailability of monacolin K was increased due to the interference of cyclosporine with the
metabolism of monacolins by mediated by CYP3A4, isoenzyme.
Chen et al. (2012) observed that three registered RYR-based products (LipoCol Forte, Cholestin,
and Xuezhikang) were more active than pure lovastatin in the in vitro inhibition of cytochrome P450
enzymes and P-glycoprotein. In an additional clinical study conducted in 14 volunteers, the
concomitant use of gemﬁbrozil with a RYR extract (LipoCol Forte) resulted in a signiﬁcant increase in
the plasma concentration and AUC of lovastatin acid (HA), without any effect on the pharmacokinetic
parameters of lovastatin lactone.
3.3.3. Conclusion of ADME
Overall, from the available database, the Panel considered that:
• orally administered lovastatin rapidly converts by esterases to its active form, lovastatin HA,
• due to its extensive ﬁrst-pass metabolism and its low solubility, intact lovastatin exhibits low
systemic bioavailability of 5%
• lovastatin and lovastatin HA are bound to human plasma proteins,
• the cytochrome P4503A-dependent oxidation at the 60-position is the major pathway of phase
I metabolism for lovastatin in humans whereas hydroxylation at the 3″-position of the side
chain is a minor pathway,
• hepatic metabolites of lovastatin are active inhibitors of HMG-CoA reductase,
• there is biliary excretion of unidentiﬁed polar metabolites of lovastatin,
• following oral administration of 14C-lovastatin in humans, 9.6% and 83.2% of the administered
radioactivity were excreted in urine and faeces, respectively,
• the bioavailability of lovastatin increases by 30–50% when taken with a standard meal,
• due to the involvement of the CYP3A4 isoform in monacolin metabolism, there is a risk of
adverse effects due to interactions with other medicinal products and foods,
in subjects given RYR extract (LipoCol Forte), plasma levels of lovastatin and lovastatin acid were
two- to ﬁvefold higher than in volunteers receiving a similar dose administered as lovastatin tablets,
but divergent data have been obtained in other pharmacokinetic studies in humans.
3.4. Adverse effects in humans
3.4.1. RYR Preparations
3.4.1.1. Adverse effects reported by international and national institutions
Several adverse effects associated with the intake of RYR-based products have been reported; the
nature of symptoms and target organs/systems are similar to those reported for lovastatin (Chen
et al., 2015b). Data from case reports (ICSRs) have been retrieved from (1) the Vigibase database
maintained by the World Health Organization (WHO) Collaborating Centre for International Drug
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Monitoring (online); (2) two publications reporting cases collected through national systems of
nutrivigilance, the French Phytovigilance (ANSES, 2014), Italian Surveillance System of Natural Health
Products (Mazzanti et al., 2017), and (3) data collected by the FDA. Appendix B illustrates these data
together with the reported level of causality.
In the period 2002–May 2018, 82 cases of adverse effects to RYR were reported to the WHO
Vigibase. The geographical distribution was as follows: 37 (45%) of them were from Americas; 2 (3%)
from Asia; and 43 (52%) from Europe. The cases occurred in 51 females (62%) and 30 males (37%);
in one case, the sex was unknown. One adverse event was reported in a child (28 days–23 month), 7
(9%) in subjects aged 18–44 years, 31 (38%) in subjects aged 45–64 years, 20 (24%) in subjects
aged 65–74 years and 3 (4%) in subjects aged > 75 years. For the remaining 19 cases (24%), the
age was unknown.
The more frequently reported adverse events were musculoskeletal and connective tissue disorders
(myalgia was the most frequently reported reaction) (39%), followed by general disorders and
administration site conditions (e.g. drug interaction, pain, fatigue) (32.9%), gastrointestinal disorders
(e.g. diarrhoea, nausea and abdominal pain) (18%).
Between April 2002 and September 2015, the Italian Surveillance System of Natural Health
Products (Mazzanti et al., 2017) collected 52 reports concerning 55 adverse reactions to food
supplements containing RYR. The majority of the cases (71%) occurred in women. The distribution of
cases among the different age groups was: 7 cases (13.5%) between 18 and 44 years; 21 cases
(40.4%) between 45 and 64 years; 13 subjects (25%) between 65 and 74 years; and 8 cases (15.4%)
in subjects > 75 years old. For three patients (13, 46 and 48), the age was unknown. The adverse
effects reported to the system were associated with 16 different food supplements. Composition of
three food supplements indicated the quantity of monacolin K with the daily dose (3 mg/day). These
food supplements whose composition was indicated were responsible (with different grade of
causality) for 34 (65%) out of 52 clinical events. In more detail, 33 cases were referred to two
products (Armolipid and Armolipid Plus) and one case to the third one (Colest 500). The most
frequently reported ‘system organ classes’ were ‘Musculoskeletal and connective tissue disorders’ (20
reactions, 36%), ‘Gastrointestinal disorders’ (12, 22%), ‘Hepatobiliary disorders’ (10, 18%), ‘Skin and
subcutaneous tissue disorders’ (9, 16%). After the cases were reviewed for causality, the association
was classiﬁed as certain (1 reaction of rhabdomyolisis in a 48-year-old woman who had experienced
the same reaction after being treated with statins), probable (31 reactions, 56%), possible (18
reactions, 34%), unlikely (3 reactions) or unassessable (2 reactions).
In 14 cases (27%), the reaction was fulﬁlling the criteria for seriousness, including 13 cases that
required hospitalisation. The hepatic reactions reported were classiﬁed as serious (acute hepatitis) in
six out of ten cases (60%) (see Appendix B).
The report published by ANSES (2014) contains reactions reported to the French nutrivigilance
system between its creation in 2009 and 31 May 2013. A total of 30 reports of adverse reactions
potentially associated with the consumption of food supplements containing RYR were included,
however only 25 had sufﬁcient information to complete the causality assessment. Also, in this case,
the majority of the cases concerned women (n = 15, 60%). The median age for the reported cases
was 59 years.
Causality was considered very likely for 2 cases, likely for 10 cases and possible for 8 cases. The
most frequently reported reactions were musculoskeletal (nine cases of muscular damage, all of them
classiﬁed as likely and very likely) and liver-related (eight cases) (see Appendix B).
Adverse effects to RYR have been reported also by FDA, through the CFSAN Adverse Event
Reporting System (CAERS), which is a post-market surveillance system, collecting information on the
adverse events for food, dietary supplements and cosmetics. Data regarding the period between
January 2004 and September 2017 can be downloaded from the FDA website (FDA, online).11 For this
opinion, the search was performed using the term ‘yeast’ and selecting cases for ‘red yeast rice’. The
few cases of reaction to yeast as such were excluded. The Panel noted that data reﬂect information as
reported by healthcare professionals, industries, agencies and consumers, so that there is no
conclusion on causality. People reporting reactions to FDA should classify them as: (1) suspected
adverse reaction (suspected) or (2) possible result of concurrent condition or activity or
co-consumption of other products (concomitant) (see Appendix B).
In the period considered, FDA collected 164 cases of possible adverse effects to RYR; 67% of them
occurred in women; 30.6% in males and in 4 cases (2.4%) the sex was not indicated. The distribution
11 https://www.fda.gov/downloads/Food/ComplianceEnforcement/UCM494018.csv
Safety assessment of monacolins
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2018;16(8):5368
of cases among the different age groups was: 6 cases (3.7%) between 36 and 44 years; 54 cases
(32.9%) between 45 and 64 years; 42 subjects (25.6%) between 65 and 74 years; 29 cases (17.7%)
in subjects ≥ 75 years old. For 33 subjects, the age was unknown.
Considering the organs/systems involved in the adverse effects reported by the 4 national/
international sources, the Panel noted that:
1) The most frequent adverse effects were reported for the musculoskeletal and connective
tissues: from 29.9% of cases of FDA to 38.4% of Italian Phytovigilance cases. In all the four
registries, cases of rhabdomyolysis were reported and, when assessed for causality, they
were considered to be in the highest ranks;
2) The gastrointestinal system was frequently involved from 12% of cases of ANSES to 23.1%
of Italian cases;
3) Skin and subcutaneous adverse effects were registered in approximately 12% of cases
(from 8% of ANSES to 17.3% of Italian cases);
4) Hepatobiliary system was the target of a signiﬁcant percentage of cases: from 8.5% of
WHO cases to 32% of ANSES ones.
3.4.1.2. Adverse effects reported by interested parties following a public ‘Call for data’
Following the launch of a public ‘Call for data’, the Panel was provided with post-marketing data
related to certain food supplements containing monacolin K from RYR with a daily recommended
intake ranges from 10 to 20 mg monacolin K/day. Eighty case reports encompassing 142 adverse
reactions have been collected. Most of them were reported under the ‘system organ classes’
‘Gastrointestinal disorders’ (24%), followed by ‘Musculoskeletal and connective tissue disorders’ (15%)
and ‘Nervous system disorders’ (15%). Eight cases involved 13 serious adverse events (impaired
gastric emptying, arrhythmia, splegia, abdominal pain upper, oropharyngeal discomfort, pharyngeal
erosion, respiratory distress, toxic epidermal necrolysis, hepatitis acute, seizure, abdominal discomfort,
dyspepsia, hepatitis). All these serious cases were spontaneous and six of them were medically
conﬁrmed. Of these six medically conﬁrmed cases, confounding factors such as advanced age and/or
concomitant medication were reported in three cases. Two of these patients recovered after withdrawn
of the product while the outcome is unknown for the remaining case. Little information is available for
the remaining three serious medically conﬁrmed cases. Patients involved in the two serious
non-medically conﬁrmed cases recovered after product withdrawal.
3.4.2. Adverse effects from clinical trials
Gerards et al. (2015) performed a systematic literature review and meta-analysis of randomised
clinical trials in which a known dose of monacolin K from RYR based-products was tested against a
control (either placebo or active treatment, including statins). A total of 20 clinical trials were included
in the meta-analysis, including a total of 6,663 patients, most of them from China. The dose of
monacolin K reported in the included studies ranged between 4.8 and 24 mg/day; subjects were
followed-up from 6 to 168 weeks. Despite the low number of adverse effects reported in the studies,
the authors conducted a meta-analysis elaborated the results and compared the incidence of health
problems in RYR-treated vs control groups (Table 8).
The authors extracted information from the studies reporting data on kidney injury (8 studies), liver
abnormalities (14 studies reporting data on liver transaminases) and muscle symptoms (10 studies
reporting creatinine kinase (CK) values or information) obtained from a validated questionnaire. There
were no signiﬁcant differences between the incidence of the events in the patients treated with RYR
compared to the controls, for any of the three endpoints. However, the authors stated that ‘risk of bias
was evident in the assessment of adverse reactions which could have led to the underestimation of the
incidence of adverse reactions in RYR groups’. The authors noted that safety assessment was not
included in all studies; some studies did not provide quantitative data and the methods for evaluating,
deﬁning and reporting adverse reactions were unclear. They speciﬁed that studies in which the
criterion was unclear the prevalence of adverse reactions was very low (0–9%) in comparison to
studies that reported all adverse reactions (30–76%).
Other adverse reactions and patient reported symptoms were classiﬁed by organ system (Table 10).
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Following the launch of a public ‘Call for data’, the Panel was aware of a study performed in 123
patients affected by hypercholesterolaemia (‘Documentation provided to EFSA’ n. 9). The patients
received two capsules per day of a RYR preparation containing 6 mg of monacolin K per capsule
(corresponding to a total daily intake of monacolin K of 12 mg) for 6 weeks. Measurements of blood
level of cholesterol and CPK were performed before starting the treatment and after the 6 weeks.
Among the 123 patients enrolled in the study, 86 never took statins before, 37 took statins irregularly
due to intolerance. No statistically signiﬁcant changes in the CK levels were observed after treatment
with monacolin K in all the 123 patients. Out of the 37 patients who had exhibited intolerance to
statins, four patients (11%) complained myalgia in the lower back (Descamps, 2013).
3.4.3. Case reports from the scientiﬁc literature
Some case reports have been published in the scientiﬁc literature. The following sections list the
published cases, where causality was assessed or where clinical data were sufﬁciently detailed.
3.4.3.1. Musculoskeletal disorders
Myopathy and rhabdomyolysis are the most frequent adverse effects associated with RYR. Most
cases were collected by ANSES (Philibert et al., 2016), and the Italian Surveillance System (Mazzanti
et al., 2017).
The most signiﬁcant data on musculoskeletal disorders have been selected and summarised in
Table 9. Other case reports describing similar adverse effects, but with intake of monacolin K
unknown, are listed below:
• an increased level of CK and muscle pain were described in two females 43- and 60-year-old,
receiving 400 and 200 mg of RYR, respectively, for 6 months (Lapi et al., 2008);
• a group of eight cases of increased level of CK, myopathy, and/or other muscle disorders,
where the intake of monacolin K was not speciﬁed, were reported by Mazzanti et al., 2017.
• after 90 days of treatment with RYR, a female (61 years old) showed diffuse myalgia and
increased level of serum CK. Both problems were solved after elimination of RYR. The same
adverse effects were previously suffered by the patient during a therapy with simvastatin
(Mueller, 2006);
• rhabdomyolysis and increased level of CK were observed in a male (37 years old) after the
intake of RYR for 60 days (Philibert et al., 2016);
• myalgia appeared in a woman (53 years old; thyroidectomy) receiving RYR (Philibert et al., 2016);
• A case in a man (46 years old) developing body aches, increased level of serum CK (10 times)
as a consequence of the intake of 600 mg of RYR has been reported by Polsani et al. (2008).
The patient suffered similar problems during a previous treatment with simvastatin;
• a case of rhabdomyolysis was observed in a 70-year-old woman in polytherapy, when she
started consuming a dietary supplement containing RYR. The adverse effect was probably due
to the interaction between monacolin K and the medicinal products sertraline and rosuvastatin
(Russo et al., 2016);
Table 8: Adverse effects reported in 36 papers (20 clinical trials) (modiﬁed from Gerards et al.,
2015)
Organ/system
RYR-treated
group
Control
group
Gastrointestinal disorders (diarrhoea, GI discomfort, other symptoms) 51 20
Muscoloskeletal (arthralgia, weakness) 15 9
Laboratory value alterations (LDL, leucocytosis, leukopenia, hyperglycaemia) 3 2
Infectious problems (inﬂuenza, urinary tract, pneumonia) 10 5
Immunologic problems (rash, alopecia, allergic reactions) 7 4
General problems (dizziness, malaise, fatigue) 6 6
CNS disorders (headache) 5 5
Cardiovascular disorders (QT prolongation, uncontrolled hypertension,
oedema, erectile dysfunction)
2 6
Miscellaneous problems (breast cancer, unspeciﬁed) 23 29
RYR: red yeast rice; LDL: low-density lipoprotein; CNS: central nervous system.
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• the association between RYR intake and myopathy was observed in a middle-aged man after
intake of a herbal preparation. A mild increase of creatine phosphokinase (CPK) level was
detected during laboratory testing; after discontinuation of the product, the CPK level returned
to normal, but when the product was resumed some months after, the increase in the CPK
level reoccurred (Smith and Olive, 2003);
• muscle weakness and increased level of CK (previously appeared with atorvastatin) were
shown by a diabetic male (76 years old) after 90 days of RYR intake (Vercelli et al., 2006);
• a case of myalgia, regurgitation of food, appetite absence, fatigue and upper abdominal pain
was observed in a 53-year-old woman, who used a RYR supplement (10 mg of monacolin K)
bought from online web shop (Venhuis et al., 2017).
3.4.3.2. Effects on the liver
Effects on the liver are among the most frequent and severe adverse effects reported in association
with the intake of RYR. As for musculoskeletal disorders, Table 10 summarised the case reports where
the intake of monacolin K, the symptomatology, and a convincing assessment of causality was
speciﬁed. Mazzanti et al. (2017) described 10 cases of hepatobiliary disorders associated with the
intake of RYR; two of them were considered unassessable/unlikely. The remaining cases are included
in the Table 10, apart from one of them where the quantity of monacolin K was not speciﬁed. In the
latter case, the patient (male, 51 years old) was hospitalised for an acute cholestatic hepatitis
appeared after 28 days of RYR intake.
Grieco et al. (2009) described the case of a 63-year-old woman, who received chronically RYR
extract (Equisterol, containing 15 mg of monacolin K) to treat hypercholesterolaemia. The product
was prescribed to replace a medicinal product containing statins, as the patient had developed
hepatotoxicity. The patient after a few weeks of intake of the RYR product showed severe elevation of
liver transaminases, and a severe lobular hepatic necrosis and inﬂammation with eosinophilic inﬁltrate
observed in liver biopsy. The case was regarded as an adverse effect to RYR, after exclusion of other
possible causes of hepatotoxicity. Lapi et al. (2008) reported three cases of patients showing increased
levels of biomarkers of liver disorders (such as alanine aminotransferase (ALT), glutaryl
aminotransferase and gamma glutamyl transpeptidase) after the use for few months of food
supplements containing RYR; two of them are included in Table 11.
A case of liver injury was described in a 62-year-old woman, who showed a 10-week history of
ﬂu-like symptoms (Roselle et al., 2008). She suffered chronic diseases (asthma, allergic rhinitis, and
depression and took (in addition to RYR 600 mg/twice a day, level of monacolin K unknown)
montelukast sodium and ﬂuoxetine. Results from laboratory analysis showed an increased level of
aspartate amino transferase (4.6 times the highest normal level), ALT (14.4 times the highest normal
level), and of the erythrocyte sedimentation rate (three times the highest normal value). Further tests
performed on the liver biopsy supported a possible drug-induced hepatitis. Clinical pattern was totally
solved with cessation of RYR product.
3.4.3.3. Gastrointestinal disorders
Mazzanti et al. (2017) collected 12 cases of gastrointestinal disorders associated with the intake of
RYR-based products; one of them was classiﬁed as unassessable. Among the 11 cases considered
probable/possible, one required hospitalisation (female, 43 years old) for severe vomiting and one
(male, 55 years old) showed severe symptoms.
3.4.3.4. Skin and subcutaneous tissue disorders
Mazzanti et al. (2017) described nine cases of skin disorders associated with the intake of
RYR-based products; two of them were classiﬁed as unlikely. Among the probable/possible cases, two
required hospitalisation: one female, 66 years old, for generalised urticaria and itching, and one female
(age unknown) for drug eruption with eosinophilia and systemic symptoms.
3.4.3.5. Other reported effects
A case of peripheral neuropathy has been described in a 60-year-old male patient, who received
contemporary imatinib to treat a metastatic gastrointestinal cancer and a food supplement containing
RYR (Kumari et al., 2013). The causality was demonstrated by the total remission of symptoms after
withdrawal of RYR preparation.
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A case of erectile dysfunction was described in a 39-year-old subject, who self-prescribed a RYR
preparation to reduce his hyperlipidaemia (Liu and Chen, 2018). Symptoms disappeared after 5 weeks
of wash out from RYR.
It has been described a case of IgE-mediated allergy to RYR in a 26-year-old man, who was
preparing sausage handling raw meats and spices (including RYR), used as preservatives (Wigger-
Alberti et al., 1999).
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Table 9: Case reports of myopathy and rhabdomyolysis associated with intake of food supplements containing monacolin K from RYR preparations,
published in the scientiﬁc literature
Patient data
Daily intake of
monacolin K
Period of
intake
Adverse effects Reference
Female, 52 years old 2.6 mg 90 days Increase level of serum CK; Myalgia Philibert et al. (2016)
Female, 53 years old 3 mg 60 days Increased level of serum CK Lapi et al. (2008)
Sex unknown, 48 years old 3 mg 60 days Rhabdomyolysis (hospitalisation) Mazzanti et al. (2017)
Female, 45 years old 3 mg 24 days Nocturnal leg muscle cramps Mazzanti et al. (2017)
Female, 45 years old 3 mg 54 days Myalgia in the leg Mazzanti et al. (2017)
Female, 53 years old 3 mg 97 days Generalised muscle aches Mazzanti et al. (2017)
Female, 57 years old 3 mg 60 days Increased level of serum CK (10 times). Mazzanti et al. (2017)
Female, 65 years old 3 mg 31 days Cramps and myalgia of lower extremities Mazzanti et al. (2017)
Female, 67 years old 3 mg 31 days Increased level of serum CK, myopathy,
asthenia. Previous myopathy by statins
Mazzanti et al. (2017)
Female, 68 years old 3 mg 62 days Localised muscle pain; increased
level of serum CK
Mazzanti et al. (2017)
Female, 69 years old 3 mg 25 days Myalgia of lower extremities Mazzanti et al. (2017)
Female, 70 years old 3 mg 90 days Myalgia, increased level of serum CK,
Previous statin intolerance
Mazzanti et al. (2017)
Female, age unknown 3 mg > 365 days Increased level of serum CK,
previously observed with statins
Mazzanti et al. (2017)
Male, 60 years old 3 mg 165 days Increased level of serum CK Mazzanti et al. (2017)
Female, 4–8 mg 4 months Myalgia Venhuis et al. (2016)
Male, 49 years old 5 mg 60 days Increased level of serum CK Lapi et al. (2008)
Female, 64 years old 10.2 mg 30 days Increase level of serum CK Philibert et al. (2016)
Female, 51 years old 19.8 mg 30 days Myalgia Philibert et al. (2016)
Male, 37 years old 19.2 mg 48 days Rhabdomyolysis, increased
level of serum CK
Philibert et al. (2016)
Female, 51 years old 19.8 mg 30 days Myalgia Philibert et al. (2016)
CK: creatine kinase.
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Table 10: Case reports of liver function alteration associated with intake of food supplements containing monacolin K from RYR preparations, published
in the scientiﬁc literature
Patient data
Daily intake of
monacolin K(a)
Period of
intake
Adverse effects Reference
Female, 63 years old 15–30 mg 6 months Severe lobular necroinﬂammatory changes at liver biopsy;
previous mild hepatotoxicity during therapy with lovastatin
Grieco et al. (2009)
Female, 53 years old 3 mg 60 days Increased level of ALT and AST, GGT Lapi et al. (2008)
Male, 49 years old 5 mg 60 days Increased level of ALT and AST Lapi et al. (2008)
Female, 42 years old 3 mg 30 days Acute hepatitis with hospitalisation Mazzanti et al. (2017)
Female, 46 years old 3 mg 50 days Acute hepatitis with hospitalisation Mazzanti et al. (2017)
Female, 58 years old 3 mg 60 days Increased level of AST (2x normal level) Mazzanti et al. (2017)
Female, 68 years old 3 mg 15 days Increased level of pancreas and hepatic enzymes Mazzanti et al. (2017)
Female, 68 years old 3 mg 1 year Increased level of transaminases; previous statin intolerance Mazzanti et al. (2017)
Male, 35 years old 3 mg 60 days Toxic acute hepatitis with hospitalisation Mazzanti et al. (2017)
Male, 36 years old 3 mg 76 days Acute hepatitis with hospitalisation Mazzanti et al. (2017)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase.
(a): Ingredients other than monacolin K may be present in the products.
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3.4.4. Lovastatin
The safety proﬁle lovastatin is described in the Summary of Product Characteristics (SPC) of the
medicinal products containing it as an active ingredient. In its opinion on the substantiation of health
claims, the NDA Panel referred to the information contained in the SPC of lovastatin with respect to
the safety proﬁle of monacolin K.
• According to the SPC for medicinal products containing lovastatin, the use of lovastatin is
contraindicated in the following cases (SCP, online):
• Hypersensitivity to lovastatin or to any of the excipients of the medicinal product
• Active liver disease or unexplained persistently elevated serum transaminase levels
• Cholestasis
• Myopathy
• Concomitant administration of potent CYP3A4 inhibitors (itraconazole, ketoconazole, HIV
protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone).
• Concomitant treatment with delavirdine, verapamil and amiodarone.
• Pregnancy and lactation
• Alcoholism.
As stated in the SPC, the use of lovastatin in children and adolescents (below 18 years) ‘is not
recommended as safety and efﬁcacy studies have not been established’.
Special warnings and precautions for use are reported for the occurrence of myopathy, an adverse
effect common to inhibitors of HMG-CoA reductase, which is manifested as muscle pain, tenderness or
weakness with increase in the values of CK above 10 times the normal upper limit (ULN). In the most
severe cases, myopathy takes the form of rhabdomyolysis with or without acute renal failure
secondary to myoglobinuria, and rare fatalities have occurred. According to the information reported in
the SPC, the risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in
plasma. The risk is also increased by the concomitant use of lovastatin with potent inhibitors of
CYP3A4, other lipid-lowering medicines that can cause myopathy and in certain subgroups of the
population.
In the initial clinical trials, marked (to more than three times the ULN) increases in transaminases
occurred in a few patients, usually appearing 3–12 months after the start of therapy with lovastatin,
but without the development of jaundice or other clinical signs or symptoms. There was no evidence
of hypersensitivity. As a precaution, the SPC recommends performing liver function tests before
initiation of therapy in patients with a history of liver disease, or when otherwise clinically indicated,
and also periodically later (e.g. every half year), particularly in patients whose results are abnormal
and/or who consume high quantities of alcohol and/or who receive doses > 40 mg lovastatin/day.
It is further recommended to test liver function in all patients prior to use of 40 mg or more daily
and thereafter when clinically indicated.
Continuation of the treatment should be reconsidered in the event of serum transaminase level
rising above three times the upper limit of normal values and the analysis should be performed again
after discontinuation of the treatment.
As with other lipid-lowering agents, moderate (less than three times the ULN) elevations of serum
transaminases have been reported during therapy with lovastatin, appearing soon after initiation of
therapy with lovastatin but usually of a transient nature and not accompanied by any symptoms. Such
mild effects were not considered to deserve interruption of treatment.
Lovastatin should be used with caution in patients who consume substantial quantities of alcohol
and/or have a past history of liver disease. Active liver disease or unexplained persistent elevations of
serum transaminases is a contraindication to the use of lovastatin.
3.4.4.1. Frequency of side effects to lovastatin
Table 11 lists the most frequent adverse effects based on data derived from clinical studies and
from post-marketing experience with lovastatin (SPC, online).
Safety assessment of monacolins
www.efsa.europa.eu/efsajournal 35 EFSA Journal 2018;16(8):5368
The Panel noted the reported adverse effects for lovastatin are consistent with those reported for
monacolin K from RYR.
3.4.4.2. Case of adverse effects collected by European Pharmacovigilance
The European Medicines Agency (EMA) is responsible for the collection of suspected adverse
reactions to human and veterinary medicines, including herbal medicines for human use. Data are
published in the Eudravigilance (http://www.adrreports.eu/en/index.html), the European database,
which can be accessed online. The Eudravigilance database exists since December 2001; the
information is regularly updated and the current status is February 2018.
Table 11: Frequency, organ class and adverse effects of lovastatin as reported in the SPC on the
basis of clinical studies and post-marketing data (SCP, online)
Frequency Organ class Adverse effect
Common
(≥ 1/100
to < 1/10)
Metabolism and nutrition disorders Digestive disorders
Nervous system disorders Vertigo, cephalagia
Eye disorders Blurred vision
Gastrointestinal disorders Flatulence, diarrhoea, constipation, nausea, dyspepsia,
abdominal pains
Skin and subcutaneous tissue
disorders
Rash
Musculoskeletal and connective
tissue disorders
Muscle cramps and myalgia
Uncommon
(≥ 1/1,000
to < 1/100)
Psychiatric disorders Insomnia, sleeping difﬁculties
Nervous system disorders Dysgeusia
Skin and subcutaneous tissue
disorders
Pruritus, xerostomia
General disorders and
administration site conditions
Tiredness
Rare
(≥ 1/10,000
to < 1/1,000)
Immune system disorders Hypersensitivity syndrome associated with one or more of the
following symptoms: anaphylaxis, angioedema, lupus-like
syndrome, polymyalgia rheumatica, dermatomyositis,
vasculitis, thrombocytopenia, leucopenia, eosinophilia,
haemolytic anaemia, positive antinuclear antibodies (ANA),
increased sedimentation rate, arthritis, arthralgia, urticaria,
asthenia, photosensitivity, fever, ﬂushes, chills, dyspnoea and
malaise
Metabolism and nutrition disorders Anorexia
Psychiatric disorders Psychological disturbances including restlessness/anxiety
Nervous system disorders Peripheral neuropathy, in particular if used for a long period of
term, paraesthesia
Gastrointestinal disorders Vomiting
Hepatobiliary disorders Hepatitis, cholestatic jaundice
Skin and subcutaneous tissue
disorders
Hair loss, toxic epidermal necrolysis and erythema multiforme
including Stevens-Johnson syndrome
Musculoskeletal and connective
tissue disorders
Myopathia and rhabdomyolysis, erectile dysfunction
Investigations Marked and persistent increases in serum transaminase
concentrations
Other irregularities in liver function tests, including elevated
alkaline phosphatase and bilirubin have been reported.
Increases in the serum concentration of CK (which may be
attributed to the non-cardiac fraction of CK) have been seen.
These have usually been slight and transient; marked
increases have only occurred in rare cases
Not known Psychiatric disorders Depression
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Information on the adverse effects to lovastatin is shown in Tables 12. Reports from countries of
the European Economic Area are approximately the 25% of total cases. The highest numbers of case
reports were from Germany (12.1%), Italy (8.3%), and Spain (2.9%). Cases were distributed among
males and females for 50.4 and 42.9%, respectively. Adverse effects involving the musculoskeletal and
connective tissues were more than 50% (53.4%); the other systems, which were frequently target of
the adverse symptomatology, were: nervous system (20.3%); gastrointestinal system (14.9%); renal
system (11.3%); hepatobiliary system (10%); skin and subcutaneous tissue (8.9%); and cardiac
system (8.3%).
4. Discussion
RYR is made by fermentation of rice with yeasts, mainly M. purpureus. RYR is traditionally used in
China for culinary purposes as a food colouring or as a traditional remedy to promote digestion and
blood circulation.
In 2013, the NDA Panel issued a scientiﬁc opinion on the substantiation of a health claim related to
monacolin K from RYR and maintenance of normal blood LDL-cholesterol concentration. The NDA
Panel concluded that a cause and effect relationship has been established between the consumption of
10 mg/day of monacolin K from RYR and the claimed effect.
Monacolin K in lactone form is identical to lovastatin, the active ingredient of several medicinal
products authorised for the treatment of hypercholesterolaemia in the EU.
Table 12: Distribution of suspected adverse effects to lovastatin reported to EMA according to the
‘system organ classes’
Target of the adverse effect Males Females UN Total
Prevalence
(%)(a)
Musculoskeletal and connective tissue disorders 436 367 63 866 53.4
Investigations 237 183 26 446 27.5
General disorders and administration site conditions 206 206 22 434 26.8
Nervous system disorders 168 145 7 329 20.3
Gastrointestinal disorders 106 125 11 242 14.9
Renal and urinary disorders 113 63 8 184 11.3
Hepatobiliary disorders 82 74 6 162 10.0
Skin and subcutaneous tissue disorders 69 68 7 144 8.9
Cardiac disorders 76 56 3 135 8.3
Injury, poisoning and procedural complications 58 65 5 128 7.9
Psychiatric disorders 70 42 2 114 7.0
Respiratory, thoracic and mediastinal disorders 52 51 4 107 6.6
Metabolism and nutrition disorders 42 42 3 87 5.4
Eye disorders 42 29 3 74 4.6
Vascular disorders 37 33 2 72 4.4
Infections and infestations 30 32 1 63 3.9
Blood and lymphatic system disorders 22 22 5 49 2.7
Neoplasm benign, malignant and unspeciﬁed 25 23 1 49 3.0
Reproductive system and breast disorders 18 9 1 28 1.7
Ear and labyrinth disorders 10 15 – 25 1.5
Immune system disorders 10 12 2 24 1.5
Social circumstances 7 14 1 22 1.4
Product issues 7 11 1 19 1.2
Congenital, familial, genetic disorders 3 11 4 18 1.1
Endocrine disorders 5 4 – 9 0.6
Pregnancy, puerperium and perinatal conditions – 4 2 6 0.4
Number of subjects with symptoms in a target organ or system/total subjects (1,622).
(a): Prevalence has been calculated according to the following equation.
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Due to the wide variability in composition of food supplements containing RYR and to the lack of
data on the safety of these mixtures, the possible role of other ingredients of food supplements on
monacolins bioactivity was not considered in this opinion.
Monacolin K and lovastatin are rapidly converted from their lactone to an identical HA form, the
latter being responsible for the inhibition of the HMG-CoA reductase enzyme involved in the
biosynthesis of cholesterol. While the acidic form is naturally occurring in RYR, in the case of lovastatin
its generation requires conversion from the lactone form.
The bioavailability of lovastatin increases by 30–50% when taken with a standard meal. Due to the
involvement of the CYP3A4 isoform in its metabolism, interactions with drugs or food ingredients which
are inhibitors of this enzyme have been described, leading to increased plasma levels of statins and
possible increased risk of toxic effects. There are indications to support the fact that the monacolin K of
the RYR may have a different concentration–time proﬁle compared to the corresponding lovastatin. Two
studies present conﬂicting results. In the ﬁrst one, the serum concentration of monacolin K (in the two
forms of lactone and HA) would be signiﬁcantly higher (approximately four times) when the subjects are
treated with equivalent dose of monacolin K from RYR or lovastatin (Chen et al., 2013). In this study, a
dose of 5–6 mg of monacolin K was considered by the authors bioequivalent to 20–40 mg of lovastatin.
The study by Li et al. (2005) indicates instead an opposite result, which could have been inﬂuenced by
the pre-treatment and simultaneous administration of grapefruit juice, a known CYP3A4 inhibitor.
Through the use of the Mintel GNPD it is possible to monitor the products containing monacolin K in the
European market over a speciﬁc period of time. The Panel conducted a search related to the introduction
of products containing monacolin K from RYR from January 2012 to February 2018. According to the
Mintel GNPD in 2012, four products containing monacolin K have been placed in the European market,
eight products in 2013, ﬁve in 2014, ﬁve in 2015, six in 2016, nine in 2017 and two in 2018.
However, the Panel noted that the search conducted with the Mintel GNPD, was not informative
with regard to the extent of use of food supplements containing monacolin K from RYR.
The Panel noted that in some cases, the intake of RYR was associated with other botanicals (either
in multi-ingredient preparations or concomitantly) or other medicinal products, which could be
responsible for any side effect. However, the reported side effects, in particular musculoskeletal side
effects with elevated CPK up to several thousand units have occurred after ingestion of monacolin K
and lovastatin but not after ingestion of other botanical ingredients.
The therapeutic dose of lovastatin ranges between 10 and 80 mg/day. Considering six clinical trials,
where RYR was the only treatment used to reduce hypercholesterolaemia, it was shown that changes
in total cholesterolaemia and LDL-cholesterolaemia were dose-dependent. The lowest intake of
monacolin K, which was effective in reducing total cholesterolaemia (11.2%) and LDL-
cholesterolaemia (14.8%) was 3 mg/day.
According to four clinical studies (Dujovne et al., 1991; Furberg et al., 1994; Weintraub et al.,
1994; Downs et al., 2001), the published case reports, and EMA Pharmacovigilance, the most frequent
adverse effects to lovastatin have as a target the following organs/systems, in decreasing order of
frequency: musculoskeletal and connective tissue, including rhabdomyolysis (53.4% of EMA reports),
nervous system (20.3%), gastrointestinal tract (14.9%), kidney (11.3%), liver (10%), skin and
subcutaneous tissue (8.9%), and other minor targets.
The Panel noted that the proﬁle of adverse effects to RYR is similar to that of lovastatin; through
consultation of four sources of case reports (WHO, ANSES, Italian Surveillance system, FDA), the most
important targets of adverse events are: 1) musculoskeletal and connective tissue (29.9–37.2% of
cases, including 1–5% of rhabdomyolysis); liver (9–32%); nervous system (when reported, 12.8–
26.9%; gastrointestinal tract (12–23.1%); skin and subcutaneous tissue (8–17.3%).
Case reports specifying the daily intake of monacolin K showed that adverse effects appeared also
with the intake of 3 mg/day for period ranging between 2 weeks and 1 year. Cases of rhabdomyolysis,
hepatitis and skin disorders occurred and required hospitalisation (Mazzanti et al., 2017).
With respect to the data collected on the safety of use of RYR (and in particular of monacolins), the
Panel identiﬁed the following uncertainties:
1) The composition and content of monacolins (and their relative abundance) in food
supplements containing RYR.
2) Monacolins in RYR are used in multi-ingredients botanical preparations, the components of
which have not been fully evaluated individually or in combination.
3) The ratio between monacolin K lactone and monacolin K HA is variable in food supplements
containing RYR.
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4) Lack of data on the bioactivity of components in RYR other than monacolin K.
5) Due to the lack of data, the safe use of monacolins in certain groups of consumers cannot
be evaluated (pregnant women, nursing women, breast-fed infants).
6) The effects of concomitant consumption of RYR-based food supplements with foods or
drugs inhibiting CYP3A4.
7) In the majority of cases, RYR-based food supplements are multi-ingredients products.
Interactions with other ingredients on the safety of monacolins are unknown.
5. Conclusion
The Panel concluded that monacolin K in lactone form is identical to lovastatin, an active ingredient
of several medicinal products.
The Panel further concluded that intake of monacolins from RYR via food supplements, could lead
to estimated exposure to monacolin K within the range of the therapeutic doses of lovastatin.
The Panel considered that the available information on the adverse effects reported in humans
were judged to be sufﬁcient to conclude that monacolins from RYR when used as food supplements
were of signiﬁcant safety concern at the use level of 10 mg/day. The Panel further considered that
individual cases of severe adverse reactions have been reported for monacolins from RYR at intake
levels as low as 3 mg/day.
The Panel concluded that exposure to monacolin K from RYR could lead to severe adverse effects on
musculoskeletal system, including rhabdomyolysis, and on the liver. In the reported cases, the product
contained other ingredients in addition to RYR. However, these reported effects, in particular
musculoskeletal effects, have both occurred after ingestion of monacolin K and lovastatin independently.
On the basis of the information available and several uncertainties highlighted in this opinion, the
Panel was unable to identify a dietary intake of monacolins from RYR that does not give rise to
concerns about harmful effects to health, for the general population, and as appropriate, for
vulnerable subgroups of the population.
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Abbreviations
ADME absorption, distribution, metabolism and excretion
ALT alanine aminotransferase
ANA antinuclear antibodies
ANS Panel EFSA Panel on Food Additives and Nutrient Sources Added to Food
ANSES Agency for Food, Environmental and Occupational Health & Safety
AST aspartate aminotransferase
ATCC American Type Culture Collection
AUC area under the curve
BfArM Federal Institute for Drugs and Medical Devices
BVL Expert Committee of Federal Ofﬁce of Consumer Protection and Food Safety
Cmax maximum concentration
CAERS CFSAN Adverse Event Reporting System
CK creatinine kinase
CNS central nervous system
CP commercial product
CPK creatine phosphokinase
CRYR Chinese red yeast rice
DMK dehydroxymonacolin K
ED50 Median effective dose
EMA European Medicines Agency
FDA Food and Drug Administration
GGT gamma -glutamyl transferase
HA hydroxy acid
HMG-CoA 3-hydroxy-3 methylglutaryl-coenzyme A
HPLC–MS/MS high-performance liquid chromatography with tandem mass spectrometry
LDL low-density lipoprotein
LDL-C low-density lipoprotein-cholesterol
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Mintel GNPD Mintel Global New Products Database
MJ monacolin J
MJA monacolin J hydroxyacid
MK monacolin K
MKA monacolin K hydroxyacid
ML monacolin L
MLA monacolin L hydroxyacid
MM MM monacolin M
MMA monacolin M hydroxyacid
MX monacolin X
MXA monacolin X hydroxyacid
NDA Panel EFSA Panel on Dietetic Products, Nutrition and Allergies
PI compactin
RYR red yeast rice
RYRP RYR powder
SD standard deviation
SmPC Summary of Product Characteristics
SPC Summary of Product Characteristics
TC total cholesterol
TDI tolerable daily intake
ULN Upper Limit of Normal
US United States
WHO World Health Organization
Safety assessment of monacolins
www.efsa.europa.eu/efsajournal 44 EFSA Journal 2018;16(8):5368
Appendix A – List of monacolins identiﬁed in RYR
Monacolin K lactone (MK) Monacolin J lactone (MJ) Monacolin L lactone (ML) Monacolin M lactone (MM) Monacolin X lactone (MX)
MK hydroxy acid (MKA) MJ hydroxy acid (MJA) ML hydroxy acid (MLA) MM hydroxy acid (MMA) MX hydroxy acid (MXA)
Dehydromonacolin K (DMK) Dihydromonacolin L (DML) 3-OH-3,5-dihydromonacolin L (HDML) Compactin (PI)
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Appendix B – Case collected by FDA and European phytovigilance Units with assessment of level of causality(a)
Organ/system involved ANSES (2009–May 2013)
Italian surveillance system
(Apr 2002–Sep 2015)
FDA (CAERS)
Number
cases for
symptom(b)
% Total
cases
Causality
Number
cases for
symptom(b)
% total
cases
Causality
Number
cases for
symptom(b)
% Total
cases
Causality
Musculoskeletal and
connective tissue
8 32.0 VL = 1
L = 7
19 36.5 L = 11
P = 8
47 28.7 SP = 31
CM = 16
Rhabdomyolysis 1 4.0 L = 1 1 1.9 C = 1 2 1.2 SP = 2
Nervous system (including
psychiatric disorders)
0 0 0 0 21 12.8 SP = 9
CM = 12
Gastrointestinal system 3 12.0 L = 2
UN = 1
12 23.1 L = 6
P = 5
UN = 1
31 18.9 SP = 21
CM = 10
Skin and subcutaneous
tissue
2 8.0 VL = 1
P = 1
9 17.3 L = 3
P = 4
UN = 2
20 12.2 SP = 10
CM = 10
Hepatobiliary system 8 32.0 L = 3
P = 4
UN = 1
10 19.2 L = 7
P = 1
UN = 2
25 15.2 SP = 8
CM = 17
Other 7 28.0 P = 3
UN = 3
EX = 1
4 7.7 L = 4 56 34.1 SP = 41
CM = 15
TOTAL CASES 25 – 52 164
NR: Not Reported; C: Certain; VL: Very Likely; L: Likely; P: Possible; UN: unassessable, unlikely; EX: Excluded; SP: Suspected; CM: concomitant.
(a): www.vigiaccess.org, https://www.fda.gov; ANSES; 2014; Mazzanti et al., 2017.
(b): Symptoms for each subject can be more than one.
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